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Zusammenfassung
Der Prozess der Proteinfaltung ist fehlerbehaftet und in dessen Verlauf entstehen
zahlreiche Proteine mit einer unnatürlichen Konformation. Solche fehlgefalteten
Polypeptide gefährden die zelluläre Proteinhomöostase, weshalb ihrer Anreiche-
rung durch spezialisierte Proteinqualitätskontroll-Systeme (PQC’s) entgegen
gewirkt wird. Diese PQC’s sorgen für die Beseitigung der unnatürlichen Protei-
ne indem sie entweder deren Rückfaltung anregen oder ihren proteolytischen
Abbau initiieren. Ein sehr bedeutender Qualitätskontrollmechanismus ist das
Ubiquitin (Ub)-Proteasom-System (UPS), an dessen Ende der Abbau von
Proteinen durch das 26S-Proteasom steht.
In Saccharomyces cerevisiae nimmt die membrangebundene RING-Ub-Ligase
Doa10 eine bedeutende Rolle in der PQC des Endoplasmatischen Retikulums
(ER) und des Nukleus ein. Doa10 katalysiert dabei die Verknüpfung K48-
verbundener Ub-Ketten auf Proteine, die entweder in der ER-Membran oder
löslich im Cytosol oder dem Nukleoplasma vorliegen. Diese Markierung leitet
die Degradation dieser Proteine ein. Interessanterweise kooperiert Doa10, im
Gegensatz zu anderen RING-Ub-Ligasen, mit zwei Ub-konjugierenden Enzymen
(E2), um ihre Substrate zu prozessieren.
In dieser Arbeit wird veranschaulicht, wie die beiden hochspezialisierten E2 En-
zyme Ubc6 und Ubc7 sequentiell agieren, um Doa10 Substrate zu modifizieren.
Zuerst wird ein einzelnes Ub-Molekül Ubc6-abhängig an ein Substrat konjugiert
(Initiation). Von diesem Rest ausgehen katalysiert Ubc7 die Ausbildung einer
K48-verbundenen Ub-Kette (Elongation). Die Fähigkeit von Ubc6 nicht nur
Lysine, sondern auch hydroxylierten Aminosäuren wie Serin und Threonin mit
Ub-Molekülen zu verknüpfen, erweitert das Substratspektrum von Doa10 und
ermöglicht die Prozessieren von Proteinen, die keine zugänglichen Lysinres-
te exponieren. Weiterhin wird gezeigt, dass ein Überangebot von Ubc6 den
Doa10-abhängigen Substratabbau beeinträchtigt. Dies weist darauf hin, dass
die Generierung eines effizienten Poly-Ub-Signals einer streng kontrollierten
Koordination beider E2 Enzyme am Doa10-Ligase-Komplex unterliegt.
PQC, Proteinabbau, Doa10-Ub-Ligase, E2 Enzyme, Ubiquitylierung von
Aminosäuren mit Hydroxylgruppe
Abstract
Protein folding is naturally error-prone and often gives rise to species that
are trapped in an aberrant conformation. The accumulation of such termi-
nally misfolded polypeptides, which threaten protein homeostasis, is prevented
by elaborate protein quality control systems (PQCs). These PQCs remove
misfolded proteins from the cell by either facilitating their refolding or by elim-
ination through proteolysis. A major cellular PQC pathway is the ubiquitin
(Ub) proteasome system (UPS), which facilitates protein degradation by the
26S proteasome.
In Saccharomyces cerevisiae, the membrane-bound RING-type Ub ligase Doa10
is a key player of PQC in the endoplasmic reticulum (ER) and the nucleus.
Doa10 promotes lysine 48-linked poly-ubiquitylation of proteins that either
reside in the ER membrane or are soluble in the cytosol or the nucleus and
thereby labels them for degradation. Strikingly, in contrast to other RING
Ub ligases, which typically employ a single Ub conjugating enzyme (E2) for
substrate ubiquitylation, the Doa10 ligase requires two of such enzymes for
client processing.
This study demonstrates that the highly specialized E2 enzymes Ubc6 and
Ubc7 act in a sequential manner on Doa10 client proteins. In a first step Ubc6
attaches a single Ub molecule to a substrate (priming), which is followed by
the elongation of this moiety with K48-linked Ub chains by Ubc7 (elongation).
The ability of Ubc6 to conjugate Ub not only to lysine but also to hydroxylated
amino acids like serine and threonine broadens the substrate range of Doa10
and allows processing of proteins, which do not expose accessible lysine residues.
Overproduction of Ubc6 was shown to impair Doa10 dependent substrate
degradation. Apparently, the generation of a productive K48-linked poly-Ub
signal requires a tightly coordinated activity of the individual E2 enzymes at
the Doa10 ligase complex.
PQC, protein degradation, Doa10 Ub ligase, E2 enzymes, non-canonical
ubiquitylation of hydroxylated amino acids
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1 | Introduction
1.1 Ubiquitin and Ub-like proteins
Ubiquitin (Ub) is a highly conserved and essential polypeptide in eukaryotes that
can be covalently attached to other proteins. Post-translational modification
with Ub, known as ubiquitylation, regulates the function of proteins and thereby
governs fundamental cellular processes like cell cycle progression, endocytosis,
DNA damage repair and protein degradation [1]. The Ub molecule encompasses
76 amino acids that adopt a highly stable β-grasp fold through a number of
hydrogen bonds and the formation of a hydrophobic core (figure 1.2 a) [2, 3].
This compact structure is important to preserve the functionality of Ub even
during acute stress conditions [4–6]. The carboxyl-terminal six residues of
Ub are highly flexible, which is a prerequisite for the attachment to target
proteins [7]. Besides three conservative amino acid substitutions, Ub is identical
from yeast to human, which demonstrates the functional importance of the Ub
structure [8]. Indeed, specific regions on the surface serve as interaction platform
for proteins with so-called Ub binding domains (UBDs) [9]. The association
with such UBD containing proteins determines the fate of a client by routing it
to specific cellular pathways. Most importantly, Ub can be conjugated to other
Ub molecules in a controlled manner thereby forming Ub chains on the target.
Individual Ub polymers expose different properties, which allows binding of
only selected UBD proteins. This highly complex "Ub code" explains how such
a small molecule can control highly divers cellular activities. Eukaryotic cells
contain other Ub-like proteins (UBLs) that share a high degree of similarity in
tertiary structure with Ub [10]. These UBLs are also covalently attached to
target molecules through separate reaction mechanisms and regulate cellular
processes like autophagy, splicing and development [11].
1
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1.2 The ubiquitylation cascade
Post-translational modification of proteins with Ub is catalyzed by an enzymatic
cascade involving three different kinds of proteins (figure 1.1). In a first step,
the Ub activating enzyme (E1) forms a reactive thioester with the C-terminus
of Ub under hydrolysis of ATP (E1˜Ub) [12]. The E1 enzyme then transfers the
activated Ub molecule to the active site cysteine of a Ub conjugating enzyme
(E2) (E2˜Ub) [13]. Finally, Ub ligases (E3) recruit E2˜Ub complexes and
bring them in close proximity to client proteins, which in turn promotes the
conjugation of the Ub molecule to acceptor sites within the substrate [14]. As
a typical product, the carboxy-group at the C-terminus of Ub is linked to the
ε-amino group of a lysine residue by a stable isopeptide bond. This reaction is
facilitated by the nitrogen atom in the amino-group, which acts as a nucleophile
and attacks the thioester linkage at the electron-deficient carbonyl carbon of
the C-terminus of Ub. Ub exposes seven lysine residues, which themself can
serve as acceptor sites for further ubiquitylation. The addition of Ub molecules
leads to the assembly of Ub chains on target proteins. E3 ligases are key
players during substrate ubiquitylation because they assure the specificity of
the reaction and in most cases they regulate the activity of the E2 enzymes.
This is also reflected by their number in eukaryotic cells. Yeast cells contain one
E1 enzyme, 13 E2 enzymes and around 100 E3 ligases [13]. In higher eukaryotes
the number of E2 enzymes (40) and E3 ligases (600 to 1000) is considerably
larger [15, 16]. Ub ligases can be classified into three subgroups. RING (Really
Interesting New Gene)-type Ub ligases mediate direct transfer of Ub from the
E2 enzyme to the target protein by providing a binding platform for E2˜Ub
complexes [14]. HECT (Homologous to E6AP Carboxy-Terminus) Ub ligases
themself contain an active site cysteine to which the Ub molecule is transferred
by an E2 enzyme before it is finally conjugated to a client protein [17]. The
least well-studied Ub ligases are the RBR (RING between RING) ligases that
combine features of both RING and HECT E3 ligases [18]. Ub ligases, which
are specialized on transferring Ub moieties to already preassembled short Ub
chains on client proteins, are so called E4 enzymes [19].
Similar to other post-translational modification ubiquitylation is reversible
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[20]. Deubiquitinases (DUBs) remove Ub molecules from target proteins by
hydrolyzing the isopeptide bond and thereby recycle Ub for other modification
events. A balanced activity of Ub conjugation and deconjugation ensures the
maintenance of a healthy cellular environment.
E1 E1
S
E2
E2
E3
Substrate
NH2
E2 SH
E3
Substrate
NH
O
Ub
Substrate
Ub
Ub
Ub
Ub
ATP + Ub        AMP + PPi E1-SH             E2-SH
Elongation of the Ub 
chain by repeating the 
reaction cycle
O
Ub
S
O
Ub
S
O
Ub
NH
O
Figure 1.1 – Schematic representation of the ubiquitylation cascade. A
Ub activating enzyme (E1) forms a reactive thioester with the C-terminus of a Ub
molecule under consumption of ATP. In a second step, the activated Ub molecule is
transferred to an active site cysteine of a Ub conjugating enzyme (E2). Subsequently
a Ub ligase (E3) recruits charged E2 complexes and client proteins and mediates the
conjugation of Ub to the target. Repetition of the ubiquitylation reaction results in
the assembly of Ub chains on substrates.
1.3 The ubiquitin code
Ub modifications come in different shapes, which all affect client proteins
in a distinct manner. In the recent years, progress in deciphering this Ub-
code has been made to assign individual cellular functions to distinct types
of Ub modifications [8]. Mono-ubiquitylation of clients controls their cellular
localization and binding to other proteins, which modulates their activity
[21, 22]. Some histones, for example, are regulated by post-translational
modification with mono-Ub. Mono-ubiquitylation of histone H2A results in
3
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silencing of gene expression and modification of histone H2B with mono-Ub
is involved in the signaling cascade of homologous recombination upon DNA
double strand breaks [23–25]. Multiple mono-ubiquitylation was also observed
on proteins, which mostly causes degradation of the respective protein by
the 26S proteasome or functional inactivation [26, 27]. Most importantly,
Ub contains seven lysine residues and six of them are exposed on its surface
(figure 1.2 a). These lysine residues themself can serve as target sites for Ub
conjugation. Homogenous Ub chains differ in their abundance within cells
with K48- and K63-linked chains making up the predominant forms and other
species being only present in minor amounts [28–30]. The topology of Ub
chains formed through linkages of different lysine residues are distinct in their
conformation (figure 1.2 b,c).
K48
K63
K6
K11
K27
K29
K33
C-terminus
N-terminus
a b
c
Figure 1.2 – Structure of single Ub and Ub chains. (a) Crystal structure of
Ub with indicated C- and N-terminus. Lysine residues are highlighted in red (PDB
ID: 1UBQ). (b) Crystal structure of a K48-linked tetra Ub polymer. The C-terminal
glycine (yellow) and lysine 48 residue (red) are highlighted. (PDB ID: 2O6V) (c)
Crystal structure of a K63-linked tetra Ub polymer. The C-terminal glycine (yellow)
and lysine 63 residue (red) are highlighted (PDB ID: 3HM3). Structural figures were
prepared using PyMOL [31].
K48-linked Ub chains, for example, adopt a compact structural arrangement
where the single Ub molecules interact through a hydrophobic patch around
4
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isoleucine 44 [32–34]. This closed conformation masks several putative inter-
actions sites for UBD proteins. K48-linked Ub chains are mainly mediating
protein degradation through the Ub proteasome system (UPS) [35, 36]. Similar
conformations have been observed for K6-, K11- and K33-linked Ub species [37–
40]. However, all structural arrangements of these di-Ub molecules vary in their
conformation, which most likely accounts for their distinct functions within
cells. K11-chains, for example, play an important role in cell cycle regulation
in higher eukaryotes [41]. K6-linked Ub chains are less-well studied but recent
findings indicate an involvement in mitochondrial homeostasis [42, 43] and
K33-linked chains are suggested to take part in post-Golgi membrane trafficking
[44]. On the contrary, Ub chains linked through lysine 29 and 63 display an
open conformation, which results in a highly flexible and extended structure
[39, 45–49]. Interaction sites on the surface of Ub are easily accessible in these
polymers. K63-linked Ub chains are involved in several cellular processes as for
example DNA repair, membrane protein transport and signal transduction [50].
In most cases K63-linked chains serve as scaffold for protein binding during
these processes. The physiological role of K29-linked chains remains elusive
but some experiments propose an involvement in epigenetic regulation and
protein degradation [51, 52]. Ub chains, which are linked through lysine 27, are
the least-well studied Ub polymers and no structure is available to date. K27
is buried within the Ub conformation (figure 1.2 a). Thus, linkage assembly
would require some conformational rearrangements within the molecule [53].
Nevertheless, recent findings implicate that K27-linked Ub chains serve as
scaffold during the DNA damage response similar to K63-linked Ub polymers
[1]. It was shown that Ub chains are also assembled through linkages on the
N-terminus of the Ub molecule (Met1-linked Ub chains) [53]. The resulting
chains exhibit a linear conformation similar to K63-linked polymers that are
involved in the regulation of inflammation and the immune response in higher
eukaryotes [54, 55]. Corresponding to this variety of Ub chain geometries, there
is a large number of UBDs, which specifically decode the conformational status
of Ub polymers [56].
The biological relevance of homogenous assembled Ub chains is well estab-
lished both in vitro and in vivo. In contrast, any significance of Ub chains
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containing heterogeneous linkage types as well as branched K48- and K11-
linked Ub chains remains to be shown. Initial experiments suggest a function
of branched Ub chains at the Anaphase Promoting Complex (APC), which
results in enhanced substrate recognition by the 26S proteasome [57, 58]. Re-
cent findings demonstrate that Ub itself is post-translationally modified by
phosphorylation and acetylation, which substantially expands the Ub code
[1]. This new kind of modification might account for an additional layer of
regulation in the Ub system.
1.4 Non-canonical ubiquitylation
In most cases Ub linkages are conjugated to ε-amino groups of lysine side chains
within target proteins. However, in recent years several new "atypical" Ub
acceptor sites were identified (figure 1.3) [59]. The N-termini of proteins harbor
a reactive amino group similar to the one in a lysine side chain. N-terminal
ubiquitylation was first identified at MyoD and subsequently shown for several
other proteins [60, 61]. This non-canonical ubiquitylation event is not only
important for the degradation of naturally occurring lysine-free proteins but
also of some proteins, which harbor internal lysine residues [60, 62]. The reason
why some proteins are ubiquitylated predominantly at their N-termini remains
elusive. This modification might represent an adaptation to ensure the robust
degradation of structural distinct proteins by one E2-E3 pair [63]. Interestingly,
N-terminal ubiquitylation competes with N-terminal acetylation of proteins and
thereby might create a new level for regulation of protein ubiquitylation and
degradation [64, 65]. Besides the N-terminal amino group of proteins, other
amino acids as serine, threonine and cysteine residues are implicated in being
acceptor sites for Ub molecules. The side chains of these amino acids expose a
nucleophile, which can attack the Ub thioester bond at the active site of the
E2. Thioester bonds of cysteine residues and Ub molecules were shown to be
relatively stable in cells thereby contradicting the claim that such linkage types
would be rapidly dissociated in the reducing environment of the cytoplasm [66].
Ubiquitylation of cysteine residues has been reported for a couple of proteins.
The peroxisomal membrane signal receptor Pex5, for example, is ubiquitylated
at a conserved cysteine residue during translocation of proteins through the
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peroxisomal membrane [67]. In most other cases cysteine ubiquitylation medi-
ates degradation of the modified protein [68–72]. Targeting of cysteine residues
for ubiquitylation might contribute for enhanced protein turnover during cell
cycle events as it was proposed for the degradation of the transcription factor
Ngn2 in mitosis [65]. Ubiquitylation of hydroxylated amino acids like serine
and threonine residues was recently shown to initiate proteolysis of several
proteins [68–70, 73]. TRCα, for example, is assumed to be ubiquitylated at its
cytoplasmic tail involving serine residues, which in turn initiates degradation of
the receptor [74]. Moreover, ubiquitylation of the non-secreted immunoglobulin
light chain NS-1 was significantly diminished upon treatment with NaOH under
wt conditions and only mutation of all lysine, serine and threonine residues
significantly stabilized the protein [75]. Thus, ubiquitylation of hydroxylated
amino acids seems to have a role in initiating proteolysis.
Substrate
NH
O
Ub
Substrate
NH
O
Ub
Substrate
O
O
Ub
Substrate
S
O
Ub
isopeptide bond (K)
peptide bond (N-terminus)
oxyester bond (S, T)
thioester bond (C)
Figure 1.3 –Possible linkage types between Ub and proteins. The C-terminus
of Ub can be covalently linked to several amino acids as lysine residues but also
cysteine, serine and threonine residues and the N-terminus of proteins.
It is not known, whether certain proteins are specifically marked with Ub on
hydroxylated amino acids to initiate their degradation or if such conjugations
can only be observed when suitable lysine residues are not present on the
client. Furthermore, most studies only indirectly indicate an involvement of
other amino acids besides lysine during ubiquitylation or solely investigate
modifications of lysine residues. Especially, cysteine, serine and threonine
ubiquitylation still lack direct evidence and also the E2 enzymes catalyzing
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such Ub conjugation are not identified to date. Summing up, it can be stated
that non-canonical ubiquitylation occurs within cells. However, frequency and
physiological relevance of such ubiquitylation events still need to be determined.
1.5 Ubiquitin conjugating enzymes
Ub conjugating enzymes (E2s) are often called ”Ub carriers”. Despite this
name, they do not constitute passive components in the ubiquitylation reaction
but play an active role in defining the length and conformation of the Ub
chain. All E2 enzymes contain a Ub conjugating (UBC) domain, which harbors
the catalytically active cysteine residue (figure 1.4) [76]. This domain folds
into a compact structure of four α-helices, which surround a four-stranded
anti-parallel β-sheet structure [77–79]. The majority of E2 enzymes exhibit
a highly conserved HPN motif, which has an important structural role in
organizing residues in close proximity of the active site cysteine (figure 1.4)
[80, 81]. Furthermore, acidic ”gateway” amino acids (UbcH5: asparagine 117,
figure 1.4) are supposedly involved in activation of the attacking lysine residue
during ubiquitylation [82–84]. E2 enzymes interact with the Ub activating
enzyme (E1) to get charged with Ub [12]. A functional E1-E2 complex can
be only established when the E1 enzyme itself is loaded with Ub. This event
induces conformational changes within E1 that in turn make the E2 binding
site accessible [85–87]. Charged E2 enzymes bind to E3 ligases to transfer Ub
onto substrates. Some E2 enzymes specifically interact with only one appointed
E3 enzyme whereas others display high promiscuity towards the selection of E3
ligases [13]. Association of E2 enzymes to ligases involves the α-helix 1 at the
N-terminus as well as loops 4 and 7 of the E2 enzyme and only slight differences
within these areas account for the specificity of the interaction [88–91]. Because
E1 and E3 enzymes occupy overlapping docking sites, the E2 enzymes commit
several rounds of binding and dissociation during Ub chain synthesis (figure
1.4) [92, 93].
Formation of Ub polymers starts with the attachment of the first Ub molecule
to a target site within a client. This process is called Ub chain initiation or
priming. Subsequently, additional Ub moieties are conjugated to this substrate-
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linked Ub, which is termed chain elongation. Some E2 enzymes, like yeast
Cdc34, catalyze both steps during client ubiquitylation [94]. However, both
ubiquitylation reactions display differences in their mechanistic details. Thus,
it has been postulated that some E3 ligase employ two E2 enzymes to catalyze
both steps independently during chain assembly. In vitro studies on the
Anaphase Promoting Complex (APC) for example, showed that the complex
employs Ubc4 for the initial attachment of Ub to substrate proteins, while
Ubc1 catalyzes subsequent extensions with homogeneous K48-linked Ub chains
[95]. Chain elongating E2 enzymes evolved structural features to specifically
recognize one lysine residue within the Ub molecule, which ensures the rapid
synthesis of homogenous Ub chains [96]. This specificity is often a self-contained
characteristic of the Ub conjugating enzyme that is not influenced through
binding to its cognate E3 ligase [97, 98]. In contrast, chain initiating E2 enzymes
are much more promiscuous in the selection of conjugation sites, which enables
them to initiate ubiquitylation on many different substrates [96].
activ e site 
cy steine
H P N  motiv e
N - terminus
h elix  1
C - terminus
E 3  bind ing
E 1 bind ing
back sid e bind ing
asparagine 117
Figure 1.4 – Conserved structure of Ub conjugating enzymes. Structure of
the E2 UbcH5 with highlighted binding sites (E3 binding: yellow; E1 binding: pink;
Ub backside binding: cyan) and important catalytic amino acids (active site cysteine:
red; HPN motive: orange; asparagine 117: purple). The figure was adapted from
Stewart et al. [15]. Structural depictions were prepared using PyMOL [31].
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The catalytic activity of E2 enzymes can be regulated in multiple ways. It
was demonstrated, for example, that non-covalent binding of Ub to a backside
interaction site on the E2 enhances activity towards chain synthesis (figure 1.4)
[99, 100]. Paradoxically, some E2 enzymes seem to be negatively affected in
their ubiquitylation activity by a similar binding event [101]. Consequently,
backside binding of Ub can have different impacts on E2 functionality most likely
depending on individual structural properties. Accessory factors of E2 enzymes
can further regulate their activity and enhance chain assembly processivity
[13]. Modulation of the activity of the E2 enzyme Ubc7 by its co-factor Cue1
is an important example for such a regulatory mechanism, which is described
in detail in section 1.9. Several E2 enzymes were reported to ubiquitylate
themselves and thereby modulate their activity [102, 103]. Summing up, it is
evident that E2 enzymes are key players during ubiquitylation and take part in
several steps of the reaction.
1.6 RING-type E3 ligases
RING (Really Interesting New Gene) domain containing E3 ligases represent
the most abundant class of Ub ligases [16]. The structural characteristics,
which are shared by all these ligases, comprise a cysteine residue containing
domain that adopts a conserved cross brace arrangement, which is stabilized
by two zinc ions (figure 1.5 a) [104]. This structure serves as a docking site
for charged E2 enzymes and stimulates the transfer of Ub to client molecules
[105]. Some RING domains need to dimerize to be functionally active [105–
107]. Structurally and functionally related to RING domains are so-called
U-box domains, which obtain their fold based on a hydrophobic core and the
interaction of polar and charged amino acids, but do not rely on zinc ions
for structural stabilization (figure 1.5 b) [108]. The most important feature
of RING domains is their ability to bind E2 enzymes charged with Ub. This
interaction is facilitated by loop 1 and 2 as well as the major α-helix 1 of the
RING domain [88, 91, 109, 110]. Importantly, RING domains exhibit a much
higher affinity for charged than for uncharged E2 enzymes, because the Ub
molecule on the E2 is part of the interaction surface [82, 83]. Ub transfer is
facilitated by the reduction of conformational freedom of the E2 bound Ub
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moiety: The C-terminus of the Ub molecule is positioned by the RING domain
in a conserved groove of the E2 enzyme, which presumably favorably orients
it for reaction with an attacking lysine residue [111]. Consequently, the rate
of thioester hydrolysis is increased by restricting the flexibility of the bound
Ub moiety [112]. Some RING E3 ligases harbor additional domains, which
interact with their cognate E2 enzymes and thereby manipulate their activity
[113, 114].
a b
helix 1
helix 1
N-terminus
N-terminus
C-terminus
loop 1loop 2
C-terminus
loop 1
loop 2
Zn2
Zn1
Figure 1.5 – Structures of RING and U-box domains. (a) Representation
of the TRAF6 RING domain with highlighted loops and central helix 1 (PDB ID:
3HCS). Coordination of two zinc ions stabilizes the cross brace fold generating a
platform for E2 binding. (b) U-box domain of Prp19 with highlighted loops and
central helix 1 (PDB ID: 2BAY). Electrostatic interactions stabilize the conformation
instead of zinc ions. Structural figures were prepared using PyMOL [31].
1.7 Protein quality control
To maintain cellular homeostasis, it is mandatory to control protein maturation
by regulating translation and folding [115]. Dysfunction in this processes are
associated with the onset of human disorders as Alzheimer’s or Parkinson’s
disease, but also several other illnesses are linked to a disturbed proteome
[116, 117]. Hence, cells evolved an elaborate protein quality control (PQC)
apparatus to ensure the integrity of its proteome [118]. PQC processes supervise
protein synthesis, assembly and disassembly of protein complexes, trafficking,
transport to different cellular compartments and function of organelles [115].
During maturation, proteins fold into their native three-dimensional structure
11
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to be functionally active. Because polypeptide chains can adopt a large number
of different conformations and the native fold depends on the cooperation of
lots of weak non-covalent interactions, this process is error-prone [119].
native
structurefolding intermediate
Ribosome
nascent 
polypeptide
misfolded conformation
(kinetically trapped)aggregate degradation
refolding by
chaperones
proteotoxic stress,
errors during translation...
Figure 1.6 – Overview of protein folding and aggregation. Proteins fold dur-
ing and after translation at the ribosome by passing through several intermediate
conformations until they reach their native three-dimensional structure. Due to
proteotoxic stress and errors during transcription and translation, misfolded confor-
mations can occur. These species might be kinetically trapped and cannot reenter the
productive folding pathway. Because these conformers tend to aggregate, which are
potentially harmful for cells, the protein quality control systems ensure their clear-
ance. Chaperones rescue such protein conformations by initiating their refolding and
irreversibly misfolded proteins are degraded. The figure was adapted from Tyedmers
et al. [120].
A typical protein passes several intermediate states until it reaches its final
native structure (figure 1.6). In some instances such intermediates represent
kinetically trapped species that cannot reenter the productive folding cycle [120].
Errors during transcription and translation, for example, might result in amino
acid substitutions, which in turn cause misfolding of the protein. Additionally,
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stress conditions such as reactive oxygen species, heat and radiation can also
cause perturbations of native protein conformations [121]. Aberrantly folded
protein species usually expose hydrophobic surfaces, which are normally buried
in their native structure. Hence, these species tend to form aggregates, which
eventually leads to cell death [122, 123]. To minimize the population of misfolded
proteins, chaperones support newly translated polypeptides during maturation
but also promote the refolding of proteins with aberrant conformations [119].
Irreversibly malfolded proteins are cleared from cells by protein degradation
mechanisms [124].
1.8 Cdc48 and the 26S proteasome
A major protein degradation apparatus in eukaryotes is the Ub proteasome
system. Substrates of this pathway are recognized by E3 quality control ligases
and subsequently modified with K48-linked poly-Ub chains. Deubiquitylating
enzymes are suggested to counteract these Ub ligases to control the amount
of degraded protein species [125]. Hence, only protein conformers, which are
stably recruited to E3 ligases, would be decorated with a Ub signals, which
initiates their degradation. Cdc48, a AAA-ATPase, acts as segregase in the Ub
proteasome pathway by extracting ubiquitylated clients from protein complexes,
membranes or chromatin [126]. In complex with its co-factors Rad23 and Dsk2,
Cdc48 transfers the ubiquitylated target proteins to the 26S proteasome for
degradation [127, 128]. The 26S proteasome is a huge protein complex with
a molecular weight of around 2.5MDa [129, 130]. It is composed of a 20S
core complex and a regulatory 19S cap unit. The core of the proteasome
harbors the proteolytic activity, which cleaves peptide linkages. The catalytic
center of the proteasome is shielded from the cytoplasm to prevent unspecific
breakdown of proteins. Access to the catalytic core is regulated by the cap
complex, which consists of a lid and a base segment. Rpn proteins of the
lid recognize ubiquitylated proteins, deubiquitylating enzymes cleave the Ub
moieties for recycling purposes and AAA-ATPases of the base unfold target
proteins, which allows their insertion into the core subunit. K48-linked tetra
Ub species were thought to be the minimal Ub signal, which is recognized
by the proteasome and initiates protein degradation [131]. However, recent
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findings indicate that also other chain linkage types as well as multiple mono-
ubiquitylation can efficiently target client proteins for proteasomal degradation
[57, 132]. Consequently, a ”ubiquitylation threshold” model was proposed in
which the amount of Ub molecules on a protein rather than the nature of
the Ub linkage is the critical factor for recognition by the 26S proteasome
[1]. Due to the activity of deubiquitylating enzymes, only stably and heavily
modified proteins would be transferred to the proteasome, which would prevent
degradation of falsely ubiquitylated protein species.
1.9 The Doa10 Ub ligase complex
Yeast Doa10 is a major Ub ligase of the endoplasmic reticulum and the nucleus
(figure 1.7) [133, 134]. It facilitates degradation of misfolded proteins during
quality control but also mediates regulated turnover of short-lived proteins
such as transcription factors. The Doa10 protein is embedded into the ER- and
the inner nuclear membrane by 14 trans-membrane segments and exposes an
N-terminal RING-CH domain into the cytoplasm [135]. Substrates of Doa10
mainly encompass integral-membrane proteins and soluble nuclear and cytoso-
lic proteins [136, 137]. It is not clear, how Doa10 engages substrate proteins.
Recently, it was demonstrated that the cytosolic conserved C-terminus of the
ligase is mandatory for ubiquitylation of a subset of clients and thus might be
involved in substrate binding [138]. Furthermore, Hsp70 and Hsp40 chaperones
are implicated to play a role during recruitment of target proteins but specific
data on this topic are not available at the moment [137, 139, 140].
Genetic data imply that Doa10 teams up with two Ub conjugating enzymes,
Ubc6 and Ubc7, for substrate ubiquitylation [141]. Ubc7 is known to catalyze
the formation of K48-linked Ub chains [142]. The catalytic core domain of
this soluble E2 harbors an atypical acidic loop, which presumably accounts
for the catalytic propensities of this enzyme [143]. The activity of Ubc7 is
tightly regulated by its binding partner Cue1. This integral protein of the ER
recruits Ubc7 to the ERAD ligases Doa10 and Hrd1 [144]. In addition, binding
to Cue1 initiates a structural rearrangement in Ubc7 and thereby activates
its chain elongation activity [145, 146]. Furthermore, Cue1 positions Ubc7 at
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the end of the Ub chain, which favors the addition of further Ub molecules
to the polymer [147]. Ubc7, which is not bound to Cue1, auto-ubiquitylates
itself presumably on its active site cysteine, which initiates its proteolysis [148].
This control mechanism ensures that Ubc7 is only active when recruited to
the ER membrane, where it is part of three ligase complexes. Besides being
a component of the Doa10 complex, Ubc7 is also found at the Hrd1 ligase,
which mediates degradation of ER luminal and integral-membrane proteins,
and as recently suggested at the Asi complex in the inner nuclear membrane
mediating ubiquitylation of transcription factors [149, 150].
RING
Doa10 ligase
Ubc7
Cue1
Ubc6
E1
26S proteasome
ER-lumen
Cytosol
Figure 1.7 – The Doa10 ligase complex. The Doa10 Ub ligase is an integral
membrane protein residing in the ER- and inner nuclear membrane with a cytosolic
N-terminal RING domain. The ligase employs two E2 enzymes: Ubc6 and Ubc7.
Both enzymes are required for Doa10-mediated substrate proteolysis.
In contrast to Ubc7, the ubiquitylation capacity of Ubc6 and its role during
Doa10-mediated substrate ubiquitylation remain elusive to date. Knockout
of UBC6 as well as its overexpression results in diminished Doa10-mediated
substrate proteolysis [151]. Ubc6 integrates into the ER-membrane through
a carboxy terminal trans-membrane anchor with the UBC domain facing the
cytosol [151]. The E2 is a short-lived protein, which is constantly degraded
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in dependency of its own activity as well as of Ubc7 and Doa10 [152]. The
region between the catalytic core domain (UBC) and the trans-membrane
segment is termed linker area and transfers instability when fused to other
proteins. Besides being part of the Doa10 ligases, it was reported that Ubc6
associates with the Asi complex in the inner nuclear membrane [153]. However,
a specific function at this complex was not shown to date. Furthermore, Ubc6
was implicated to participate in the ubiquitylation of CPY*, an ER-luminal
Hrd1 ligase substrate [154]. However, detailed data on the role of Ubc6 at the
Hrd1 ligase are not available.
1.10 Aims of the thesis
In contrast to other RING-type Ub ligases, which typically co-operate with a
single E2 enzyme for substrate ubiquitylation, Doa10 employs two of such en-
zymes, Ubc6 and Ubc7. Remarkably, only a balanced activity of both enzymes
at the ligase ensures efficient substrate processing: Overexpression of UBC6 im-
pairs the degradation of Doa10 client proteins to a similar extent than observed
in cells lacking UBC6. The aim of this work was the functional characterization
of Ubc6 and Ubc7 and their operational interplay at the Doa10 ligase. To
this end two experimental strategies were designed that in combination should
reveal the mechanistic details of Doa10-mediated substrate ubiquitylation.
On the one hand a powerful in vitro assay should be developed to investigate
the enzymatic properties of Ubc6 and Ubc7. Using purified components, each
of the E2 enzymes in combination with the Doa10 RING-finger domain were
to be investigated for their ability to synthesize Ub conjugation under defined
conditions. By changing individual parameters, such as the variable combina-
tion of components or the employment of different Ub variants, such reactions
allow the detailed investigation of the catalytic propensities of E2 enzymes.
However, the significance of the in vitro approach is apparently limited because
only the cytosolic soluble parts of the involved membrane-bound proteins could
be studied.
Hence, Ubc6 and Ubc7 were also to be investigated in intact yeast cells to
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review the results from the in vitro work. Studies on the degradation as well as
the ubiquitylation pattern of selected client proteins in strains lacking individual
components of the Doa10 degradation pathway would serve to characterize the
function of each factor in more detail.
The results of both experimental strategies promised to reveal a compre-
hensive picture, on how the combined activity of two highly specialized E2
enzymes ensures the efficient poly-ubiquitylation of the highly heterogeneous
substrate pool of the Doa10 Ub ligase.
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2 | Material and methods
2.1 Material
2.1.1 Chemicals
Chemicals and reagents applied in this thesis, unless otherwise noted, were
purchased from Sigma, VWR and Roth. Restriction enzymes were purchased
from New England Biolabs (NEB). Buffer solutions were prepared with ddH2O,
which was deionized with a Milli-DI R© system (Millipore).
2.1.2 Antibodies
Purchased primary and secondary antibodies as well as primary antibodies
manufactured in the laboratory of Prof. Sommer are listed in table 2.1.
Table 2.1 – Antibodies applied in this thesis
Antibody Reference
Primary antibodies
Monoclonal α-Ub (P4D1), mouse Santa Cruz Biotechnology
Monoclonal α-FLAG, mouse Sigma (F3169)
Monoclonal α-HA, mouse Sigma (H9658)
Monoclonal α-CPY, mouse Thermo Fischer Scientific (A6428)
Monoclonal α-GFP, mouse Living colors (JL-8)
Polyclonal α-GFP, rabbit Life Technologies (A11122)
Polyclonal α-Myc, rabbit CST (71D10)
Polyclonal α-Sec61, rabbit (214) Biederer et al. [144]
Polyclonal α-Cue1, rabbit (259) Biederer et al. [144]
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Polyclonal α-Doa10, rabbit (250) Bagola et al. [142]
Polyclonal α-Ubc6, rabbit (120-3) Walter et al. [152]
Polyclonal α-Ubc6, rabbit (286) Weber et al. [155]
Polyclonal α-Ubc7, rabbit (277) Neuber et al. [156]
Polyclonal α-Cdc48, rabbit (282) Neuber et al. [156]
Polyclonal α-Sbh2, rabbit (24-54) Finke et al. [157]
Secondary antibodies
Polyclonal α-mouse-IgG Sigma (A9044)
HRP-conjugated, rabbit
Polyclonal α-rabbit-IgG Sigma (A0545)
HRP-conjugated, goat
Polyclonal α-rabbit-IgG LI-COR
IRDye R©800CW-conjugated, goat
2.1.3 Yeast strains
All yeast strains used in this study are haploid descendants of DF5, which has
the following genotype: MATa/alpha trp1-1(am)/trp1-1(am) his3-∆200/his3-
∆200 ura3-52/ura3-52 lys2-801/lys2-801 leu2-3,-112/leu2-3,-112 [5]. Genotype
variants of yeast strains are listed in table 2.2.
Table 2.2 – Yeast strains with relevant genotype applied in this thesis
Denotation Genotype Reference
YTX949 prc1-1 Bagola et al. [142]
YTX996 ∆ubc6::HIS3, prc1-1 Weber et al. [155]
YTX154 ∆ubc7::LEU2, prc1-1 laboratory of Prof. Som-
mer
YAW021 Ubc7C89S, prc1-1 this study
YBM74 ∆doa10::kanMX6 Birgit Meusser
YTX112 ∆ssh1::HIS3 Weber et al. [155]
YTX113 ∆ssh1::HIS3,
∆ubc7::LEU2
Weber et al. [155]
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YTX131 ∆ssh1::HIS3,
∆ubc6::LEU2
Weber et al. [155]
YAW032 ∆ssh1::HIS3,
∆doa10::kanMX6
Weber et al. [155]
YTX127 ∆ssh1::HIS3,
∆sbh2::TRP1
Weber et al. [155]
YTX126 ∆ssh1::HIS3,
∆sbh2::TRP1,
∆ubc7::LEU2
Weber et al. [155]
YAW065 ∆ssh1::HIS3,
∆sbh2::TRP1,
∆ubc6::HIS3
Weber et al. [155]
YAW067 ∆ssh1::HIS3,
∆sbh2::TRP1,
∆doa10::kanMX6
Weber et al. [155]
YAW073 ∆ssh1::HIS3, rpt4R Weber et al. [155]
YAW074 ∆ssh1::HIS3,
∆doa10::kanMX6,
rpt4R
Weber et al. [155]
YAW076 ∆ssh1::HIS3,
∆ubc6::HIS3, rpt4R
Weber et al. [155]
YAW077 ∆ssh1::HIS3,
∆ubc7::LEU2, rpt4R
Weber et al. [155]
YAW003 TEF2-doa10::NatNT2,
prc1-1
this study
YUL26 Doa10-13×Myc::HIS3 Uwe Lenk
YON26 Doa10C93S-
13×Myc::HIS3
Oliver Neuber
2.1.4 Plasmids
Plasmids applied in this thesis are listed in table 2.1.4 with encoding insert and
plasmid backbone. For yeast expression plasmids, inserts were under control
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of the corresponding endogenous promoter, unless otherwise noted. Plasmids
pTR990, pTR1646 and pTR1543 were gifts from Tommer Ravid [155, 158] and
plasmid pTX481 from Cynthia Wolberger [159].
Table 2.3 – Plasmids applied in this thesis
Denotation Backbone Encoded proteins Reference
Bacterial expression plasmids
pTX249 pGEX-6p1 Ubc7 (2-165) Bagola et al. [142]
pTX327 pGEX-6p1 Doa10R (2-125) Bagola et al. [142]
pTX352 pQE60 Ubc6∆TM-His6 (1-230) Weber et al. [155]
pTX401 pQE60 Ubc6C87S∆TM-His6 (1-
230)
Weber et al. [155]
pTX410 pGEX-6p1 Cue1∆TM-His6 (24-203) Bagola et al. [142]
pTX481 pET21d Uba1-His6 Berndsen et al.
[159]
pAW039 pGEX-6p1 Ubc6∆TM (2-230) Weber et al. [155]
pAW040 pGEX-6p1 Ubc6∆L (2-164) this study
pAW128 pGEX-6p1 Ubc6S196A∆TM (2-230) Weber et al. [155]
pAW140 pGEX-6p1 Ubc6Y66A∆TM (2-230) this study
pAW133 pGEX-6p1 UBE2J2∆TM-HA3 (1-
235)
Weber et al. [155]
pMD008 pGEX-6p1 Yeast UbS20C Bagola et al. [142]
pAW101 pGEX-6p1 Doa10RI41A (2-125) Weber et al. [155]
pAW102 pGEX-6p1 Doa10RR43A (2-125) Weber et al. [155]
pAW103 pGEX-6p1 Doa10RW73A (2-125) Weber et al. [155]
pAW074 pGEX-6p1 Ubc6∆K11 (2-230) this study
pAW097 pGEX-6p1 Doa10RK119R (2-125) this study
pTR1543 pET14 FLAG-Ub Cohen et al. [158]
Yeast expression plasmids
pAW123 pRS416 Sbh2 Weber et al. [155]
pAW124 pRS416 Sbh2K48R Weber et al. [155]
pAW125 pRS416 Sbh2K15R, K23R, K25R, K28R Weber et al. [155]
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pTR1646 pRS414 FLAG-Sbh2 Weber et al. [155]
pAW135 pRS414 FLAG-
Sbh2K15R, K23R, K25R, K28R
Weber et al. [155]
pAW027 pRS416 Ubc6 Weber et al. [155]
pAW028 pRS426 Ubc6oe this study
pAW041 pRS416 Ubc6C87S Weber et al. [155]
pAW091 pRS416 Ubc6-Linker (165-251),
Cup-promoter
this study
pAW136 pRS416 Ubc6Y66A this study
pAW047 pRS424 Myc-Ub, CUP-promoter Weber et al. [155]
pTR990 pRS317 Ub, CUP-promoter Weber et al. [155]
pJU267 pRS426 Cue1oe, Ubc7oe Jörg Urban
pJU287 pRS426 Ubc6oe, Cue1oe, Ubc7oe Jörg Urban
pUL038 pRS414 Deg1-GFP2 Lenk et al. [160]
pAW068 pRS416 Ubc6K151R this study
pAW070 pRS416 Ubc6K132R, K133R this study
pAW071 pRS416 Ubc6∆K11 this study
pAW075 pRS416 Ubc6K132R, K133R, K151R this study
2.1.5 Oligonucleotides
Oligonucleotides were purchased from BioTez GmbH (Berlin). Oligonucleotides
used for this study are listed in table 2.1.4. Katrin Bagola designed the primer
pair Ubc6C87Sfw/rev. Mismatching bases of site-directed mutagenesis primer are
indicated with lowercases as well as restriction sites in gene amplification primer.
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Table 2.4 – Oligonucleotides applied in this thesis; fw = forward primer, rev =
reverse primer
Denotation Description Sequence 5’ to 3’
Primer for site-directed mutagenesis
AW85 Ubc6 (K221R
K222R
K225R) fw
GAAAATAATTCCAgGAgAGATGGCAgA
GAACCTAATGATAG
AW86 Ubc6 (K221R
K222R
K225R) fw
CTATCATTAGGTTCTcTGCCATCTcTCc
TGGAATTATTTTC
AW92 Ubc6 (K188R
K191R
K193R) rev
GATGAAACAGAAGACCCTTTTACAg
AGGCTGCGAgGGAAAgAGTCATCTC
GTTGGAGG
AW93 Ubc6 (K188R
K191R
K193R) rev
CCTCCAACGAGATGACTcTTTCCcTCG
CAGCCTcTGTAAAAGGGTCTTCTGT
TTCATC
AW95 Ubc6 (K167R
K169R) fw
GTAGAGACATTAGAAAgGAGAAgATTG
GATGAGGGGGATGCGGC
AW96 Ubc6 (K167R
K169R) rev
GCCGCATCCCCCTCATCCAATcTTCTC
cTTTCTAATGTCTCTAC
AW143 Ubc6 (K132R
K133R) fw
CAATTACAACATCAGACCATCAGAgGA
gGACATTAGCAAGAAATTCC
AW144 Ubc6 (K132R
K133R) rev
GGAATTTCTTGCTAATGTCcTCcTCTG
ATGGTCTGATGTTGTAATTG
AW145 Ubc6
(K151R) fw
CTTTTCAAAATGTTAGATTCAgATTGA
TTTTTCCGGAAG
AW146 Ubc6
(K151R) rev
CTTCCGGAAAAATCAATcTGAATCTAA
CATTTTGAAAAG
AW175 Doa10
(K119R) fw
CCTTTTTCTTTACTACTATCCAgGAGC
ATCTTGACATTTTTC
AW176 Doa10
(K119R) rev
GAAAAATGTCAAGATGCTCcTGGATAG
TAGTAAAGAAAAAGG
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AW198 Doa10 (I41A)
fw
CCGGCGCCACCTGCCGTgcTTGTCGTG
GAGAAGCTACTG
AW199 Doa10 (I41A)
rev
CAGTAGCTTCTCCACGACAAgcACGGC
AGGTGGCGCCGG
AW200 Doa10
(R43A) fw
CCGGCGCCACCTGCCGTATTTGTgcTG
GAGAAGCTACTGAGGAC
AW201 Doa10
(R43A) rev
GTCCTCAGTAGCTTCTCCAgcACAAAT
ACGGCAGGTGGCGCCGG
AW202 Doa10
(W73A) fw
GCATGAATCCTGTCTGTTGGAAgcGG
TAGCTTCAAAAAATATAG
AW203 Doa10
(W73A) rev
CTATATTTTTTGAAGCTACCgcTTCCA
ACAGACAGGATTCATGC
AW220 Sbh2 (K15R
K23R K25R
K28R) fw
GCGTATCTTGCAGaGgAGAAGACAGG
CACAATCCATTaGgGAAaGgCAAGCA
aGaCAAACGCCCACTTCC
AW221 Sbh2 (K15R
K23R K25R
K28R) rev
GGAAGTGGGCGTTTGtCtTGCTTGcCtT
TCcCtAATGGATTGTGCCTGTCTTC
TcCtCTGCAAGATACGC
AW222 Sbh2 (K48R)
fw
CGGTGGGTCTTCAAGCTCAATTTTGa
GgTTATATACGGACGAAGCC
AW223 Sbh2 (K48R)
rev
GGCTTCGTCCGTATATAAcCtCAAAATT
GAGCTTGAAGACCCACCG
AW227 Ubc6 (S196A)
fw
GCGAAGGAAAAAGTCATCgCGTTGGA
GGAAATTCTAGACC
AW228 Ubc6 (S196A)
rev
GGTCTAGAATTTCCTCCAACGcGATGA
C TTTTTCCTTCGC
AW241 Ubc6 (Y66A)
fw
CTTTCCCGTCTGATTATCCAgcCAAACC
ACCGGCTATCAG
AW242 Ubc6 (Y66A)
rev
CTGATAGCCGGTGGTTTGgcTGGATAA
TCAGACGGGAAAG
Ubc6C87Sfw Ubc6 (C87S)
fw
CCCAACACACGATTATcgCTTTCTATGA
GTGAT
Ubc6C87Srev Ubc6 (C87S)
rev
ATCACTCATAGAAAGcgATAATCGT
GTGTTGGG
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Primer for gene amplification
AW111 Ubc6 fw cgggatccGCTACAAAGCAGGCTC
AW117 Ubc6∆TM
rev
ccgctcgagtcaACTATCATTAGGTTCTTTG
C
AW118 Ubc6∆L rev ccgctcgagtcaTGTCTCTACATTTTCCTG
AW122 1×Myc-Ub
fw
gaattcATGGAACAAAAACTTATTTCTG
AAGAAGATCTGCAGATCTTCGTCAA
GACG
AW123 Ub rev atcgatTCAACCACCTCTTAGTC
AW136 Ubc6 termina-
tor rev
ccatcgatGTTTCTTGGTCAATACATACTC
AW163 Ubc6 linker
and TM fw
ggaattcatgTTAGAAAAGAGAAAATTGGA
TG
AW212 Sbh2 pro-
moter fw
cggaattcGTGCTGTAACAATAAGGC
AW213 Sbh2 termina-
tor rev
ataagaatgcggccgcCGAAGTCGAACAAGA
GG
AW238 UBE2J2 fw ggaattcATGAGCAGCACCAGC
AW233 UBE2J2∆TM-
3×HA-tag
rev
ataagaatgcggccgcTCATCAGCACTGAGC
AGCGTAATCTGGAACGTCATATGGA
TAGGATCCTGCATAGTCCGGGACGT
CATAGGGATAGCCCGCATAGTCAGG
AACATCGTATGGGTAAAAGATGTTC
GCCAGGGCG
2.2 Molecular biological methods
2.2.1 Polymerase chain reaction (PCR)
Polymerase chain reactions were performed with the Expand High Fidelity PCR-
System (Roche). In a first reaction step, the DNA template was denaturized for
4min at 95 ◦C, followed by a cycle with 25 to 30 repetitions: first denaturation
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at 95 ◦C for 30 s, followed by an oligonucleotide annealing step at 50 ◦C for 30 s
and finished with an elongation step at 68 ◦C for 1min/kb. The reaction ended
with a final elongation step for 10min at 68 ◦C. The PCR reaction mixture
had a final volume of 50 µL.
2.2.2 Site-directed mutagenesis of plasmid DNA
Point mutations were integrated into plasmid DNA with the Pfu UltraTM HF
DNA polymerase (Agilent Technologies) according to the manufacturers manual
QuikChange R© Site Directed Mutagenesis Kit (Aligent Technologies).
2.2.3 Cloning, DNA purification and transformation of
Escherichia coli with plasmid DNA
Restriction digestion of DNA was conducted with restriction enzymes purchased
from New England Biolabs (NEB) according to the manufactures protocol.
DNA fragments were diluted with OrangeG loading dye (5×buffer: 0.25%
(w/v) OrangeG, 50% (v/v) glycerol, 5mM EDTA pH8.0) and separated by gel
electrophoresis with agarose gels (0.8-2% (w/v) agarose in TAE buffer (40mM
Tris-HCl pH8.2, 0.14% (v/v) acetic acid, 1mM EDTA)). Gels contained
the fluorophore RedSafeTM (IntRON Biotechnologies) for DNA visualization.
DNA fragments were purified from gels with the help of the Wizard R© SV
Gel and PCR Clean-Up Systems (Promega). Digested and purified insert
and vector DNA were ligated with the T4 DNA ligase (NEB) at 16 ◦C over
night. The newly generated plasmid DNA was transformed into Escherichia
coli XL1-blue cells (Aligent Technologies) by electroporation. Bacterial cells
were resuspended in 0.5mL SOC medium (2% (w/v) BactoTM tryptone, 0.5%
(w/v) BactoTM yeast extract, 10mM NaCl, 2.5mM KCl, 10mM MgCl2, 10mM
MgSO4, 0.2% (w/v) glucose) after transformation and incubated for 30min
at 37 ◦C. Afterwards, they were plated on LB-Agar (2% (w/v) agar-agar, 1%
(w/v) BactoTM tryptone, 0.5% (w/v) BactoTM yeast extract, 1% (w/v) NaCl)
containing the appropriate antibiotic marker (final concentration: ampicillin
50µg/mL, kanamycin 25µg/mL) and incubated over night at 37 ◦C.
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2.2.4 Escherichia coli cultivation, plasmid DNA purifica-
tion and sequencing
Single colonies of bacteria were picked from LB-plates and cultivated in 3mL
LB-medium (1% (w/v) BactoTM tryptone, 0.5% (w/v) BactoTM yeast extract,
1% (w/v) NaCl) containing the appropriate antibiotic marker (final concen-
tration: ampicillin 50µg/mL, kanamycin 25µg/mL) over night at 37 ◦C and
200 rpm. Plasmid DNA was isolated from bacterial cells with the help of the
JetStarTMPlasmid Purification Kit (Genome GmbH): 2mL bacterial over night
culture were pelleted (5000× g, 3min) and resuspended in 150 µL solution E1
(50mM Tris-HCl pH 8.0, 10mM EDTA, 0,1mg/mL RNase A (Roth)). For basic
cell lysis 150 µL solution E2 (0.2M NaOH, 1% (w/v) SDS) were added and care-
fully inverted. Addition of 150 µL solution E3 (3,1M potassium acetate pH 5.5)
neutralized the basic pH from solution E2. Precipitated proteins and genomic
DNA were pelleted (20,000× g, 10min) and the supernatant was transferred
into a fresh Eppendorf tube. The plasmid DNA was precipitated with addition
of 1mL cold ethanol and pelleted (21,000× g, 4 ◦C, 10min). The supernatant
was removed, the pellet dried at room temperature and subsequently suspended
in 50 µL ddH2O. The final nucleic acid concentration was determined with a
NanoDrop2000 (Thermo Scientific, PeqLab Biotechnologie GmbH). Samples
were analyzed by the company SourceBioScience Germany GmbH to validate
the sequence of the newly generated plasmid DNA.
2.2.5 Isolation of genomic DNA from yeast cells
5 to 10 OD600 of exponentially growing yeast cells were harvested by centrifu-
gation (2000× g, 3min) and the pellet was washed with 1mL ddH2O before it
was resuspended in 200 µL DNA preparation buffer (10mM Tris-HCl pH8.0,
100mM NaCl, 1mM EDTA, 1% (w/v) SDS, 2% (v/v) Triton X-100). 200 µL
phenol-chloroform-isoamyl alcohol (49.5:49.5:1) were added before cells were
lyzed by vigorous shacking with glass beads. The mixture was diluted with
200µL 1×TE buffer (10mM Tris-HCl pH8.0, 1mM EDTA) and centrifuged
(21,000× g, 10min) for phase separation. The upper, aqueous phase was har-
vested and mixed with 1mL cold ethanol. Precipitated nucleic acids were
centrifuged (21,000× g, 4 ◦C, 5min) and the pellet was resuspended in 400 µL
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1×TE buffer containing 30 µg RNase A (Roth). The mixture was incubated
for 10min at 37 ◦C to remove precipitated RNA. Ammonium acetate (final con-
centration 100mM) and 1mL ethanol were added to precipitate the remaining
DNA (21,000× g, 4 ◦C, 2min). The DNA pellet was washed with 70% (v/v)
ethanol, dried at room temperature and resuspended in 100 µL ddH2O.
2.3 Biochemical methods
2.3.1 Preparation of yeast cell lysates
5 to 10 OD600 logarithmic growing yeast cells were harvested (2000× g, 2min)
and the pellet was suspended in 100 µL lysis buffer (50mM Tris-HCl pH7.5,
1% (w/v) SDS). Yeast cells were lyzed by vigorous shacking with glass beads
for 2min. 100µL 2× SDS sample buffer (135mM Tris-HCl pH6.8, 20% (v/v)
glycerol, 4% (w/v) SDS, 0.05% (w/v) bromophenol blue, 200mM DTT)
were added and the lysate was incubated at 65 ◦C for 15min. Samples were
centrifuged at 1000× g for 5min to separate glass beads and cell debris from
cell extract. The supernatant was collected and analyzed by SDS-PAGE and
immunoblotting (see section 2.3.5 and 2.3.7).
2.3.2 Isolation of membranes from yeast cells
5 to 10 OD600 logarithmic growing yeast cells were harvested (2000× g, 2min)
and the pellet was resuspended in 400µL membrane preparation buffer (50mM
Tris-HCl, 5mM EDTA, 1mM PMSF, pH 7.5). Yeast cells were lyzed by vigorous
shacking with glass beads for 2min and the lysate was diluted with 1mL
membrane preparation buffer. To remove cell debris and glass beads, samples
were centrifuged at 1000× g for 5min at 4 ◦C. The supernatant was collected
and again centrifuged (20,000× g, 10min, 4 ◦C) to enrich cellular membranes.
The supernatant was removed, the membrane pellet was resuspended in 50 µL
4× urea sample buffer (200mM Tris-HCl pH 6.8, 5% (w/v) SDS, 0.1mM EDTA,
8M urea, 0.05% (w/v) bromophenol blue, 100mM DTT) and incubated for
20min at 42 ◦C. Samples were analyzed by SDS-PAGE and immunoblotting
(see section 2.3.5 and 2.3.7).
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2.3.3 Non-denaturing immunoprecipitation (Co-IP) of
Doa10-13×Myc variants
60 to 80 OD600 logarithmically growing yeast cells were harvested (2000× g,
2min) and washed in 4mL cold ddH2O containing 1mM PMSF for protease
inhibition. The following steps were all performed on ice and all used solutions
contained 1mM PMSF. The cell suspension was transferred to 15mL Falcon R©
tubes and centrifuged (2000× g, 2min). The pellet was suspended in 1mL
Doa10 IP buffer (50mM Tris-HCl pH 7.5, 200mM sodium acetate, 1mM EDTA,
10% (w/v) glycine, 10mM DTT) and cells were lyzed by vigorous shacking
with glass beads for 3min. The lysate was diluted with 2mL Doa10 IP buffer
and centrifuged at 1000× g for 5min to remove cell debris. The supernatant
was again centrifuged (20,000× g, 10min, 4 ◦C) to pellet membranes. The
membrane pellet was then solubilized in 500µL solubilization buffer (Doa10
IP buffer + 5% (v/v) digitonin) and incubated for 1 h at 4 ◦C under constant
stirring. Afterwards, samples were centrifuged (20,000× g, 10min, 4 ◦C) to
remove remaining membrane parts. The supernatant was collected and 35 µL
were taken as input control and mixed with 15 µL 4×urea sample buffer
(200mM Tris-HCl pH6.8, 5% (w/v) SDS, 0.1mM EDTA, 8M urea, 0.05%
(w/v) bromophenol blue, 100mM DTT) and incubated at 42 ◦C for 20min.
The remaining supernatant was diluted 1:1 with Doa10 IP-buffer to reduce
the digitonin concentration to 0.5%. 15 µL ProteinA-SepharoseTM4FastFlow
(GE Healthcare) and 1µL α-Myc antibody (M5546, SIGMA) were added to
the mixture for Doa10-Myc precipitation and incubated over night at 4 ◦C
under constant stirring. In a next step SepharoseTM was washed 3 times with
500µL wash buffer (50mM Tris-HCl pH7.5, 200mM sodium acetate, 1mM
EDTA, 10% (w/v) glycine, 0.5% digitonin). After washing, 50 µL 4×urea
sample buffer were added to the dried SepharoseTM and incubated for 20min
at 42 ◦C to elute proteins. 10µL input as well as 10µL eluate were analyzed by
SDS-PAGE and subsequent immunoblotting (see section 2.3.5 and 2.3.7).
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2.3.4 Immunoprecipitation of ubiquitylated proteins
from yeast cell lysates
Doa10 substrates as FLAG-Sbh2 variants and Ubc6 variants were isolated from
yeast cells overexpressing wt Ub or Myc-tagged Ub. 80 to 100 OD600 cells in
exponential growth phase were harvested (2000× g, 2min, 4 ◦C) and washed
in 4mL cold ddH2O containing 1mM PMSF and 20mM NEM. Cells were
lyzed by vigorous shacking in 1mL urea lysis buffer (6M urea, 50mM Tris-HCl
pH7.5, 150mM NaCl, 1% (v/v) SDS, 1mM PMSF, 20mM NEM) with glass
beads for 3min. The lysate was diluted with 9 volumes of IP dilution buffer
(55mM Tris-HCl pH7.5, 165mM NaCl, 5.5mM EDTA, 1.1% (v/v) Triton
X-100, 1mM PMSF, 20mM NEM) and cleared from remaining cell debris by
centrifugation (20,000× g, 10min, 4 ◦C). For input controls, 75 µL sample were
mixed with 25 µL 4× SDS sample buffer (250mM Tris-HCl pH6.8, 40% (v/v)
glycerol, 8% (w/v) SDS, 0.05% (w/v) bromophenol blue, 100mM DTT) and
incubated at 65 ◦C for 15min. FLAG-tagged proteins were precipitated with
50 µL ANTI-FLAG R©M2 Affinity Gel (Sigma) which was added to the lysate
and incubated over night at 4 ◦C under constant stirring. Other proteins such as
Ubc6 were isolated from cell lysate with 40 µL ProteinA-SepharoseTM4FastFlow
(GE Healthcare) and 2µL specific antibody. In a next step, beads were washed
3 times with IP dilution buffer, which was followed by protein elution with
50µL 4 ×SDS sample buffer without DTT for 15min at 42 ◦C. Finally, the
supernatant was collected and DTT (final concentration 25mM) was added
and incubated for 15min at 65 ◦C. Samples were analyzed by SDS-PAGE and
subsequent immunoblotting (see section 2.3.5 and 2.3.7). When IP samples
were incubated with NaOH, experiments were performed with double amount
of yeast cells. The eluted protein mixture was split after the first incubation
step with 4×SDS sample buffer and NaOH (final concentration 150mM) or
the equivalent amount of ddH2O was added together with DTT to the samples.
Incubating the samples for 15min at 65 ◦C removed the ubiquitylation on
hydroxylated amino acids.
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2.3.5 SDS polyacrylamide gel electrophoresis
(SDS-PAGE)
Proteins were separated based on their molecular weight with a discontinuous
SDS polyacrylamide gel electrophoresis in LRB buffer (50mM Tris-HCl pH,
383mM glycine, 0.1% (w/v) SDS) based on a protocol published by Lämmli et
al. [161]. In a first step, proteins were concentrated in a 3% stacking gel (3%
(v/v) acrylamide, 0.15% (v/v) bis-acrylamide, 125mM Tris-HCl pH6.8, 0.1%
(v/v) SDS, 0.25% (v/v) TEMED, 2.5% (v/v) APS) with a voltage of 80V
for approximately 30min. In a second step, proteins were separated in a 9 to
18% separating gel (9-18% (v/v) acrylamide, 0.06-0.09% (v/v) bis-acrylamide,
500mM Tris-HCl pH8.8, 0.1% (v/v) SDS, 0.25% (v/v) TEMED, 2.5% (v/v)
APS) with a voltage between 100V and 140V for approximately 90min. For
direct protein detection, gels were incubated with a Coomassie staining solution
(45% (v/v) methanol, 10% (v/v) acetic acid, 0.25% (w/v) Coomassie Brilliant
Blue R-250) for 30min and destained with ddH2O over night. For specific
protein detection gels were applied to protein immunoblotting. Protein markers
were purchased from Thermo Fisher Scientific (PageRulerTM Prestained Protein
Ladder) and New England Biolabs (Color Protein Standard, broad range).
2.3.6 Fluorescence scanning
Alexa488 fluorophore labeled proteins were visualized directly from SDS-PAGE
gels with a fluorescence scanner (Typhoon FLA9500 Biomolecular Imager, GE
Healthcare). The fluorescent dye was excited at 473 nm and emission was
detected with a LBP filter (510LP).
2.3.7 Western blotting (protein immunoblotting)
For specific protein detection, separated proteins from SDS-PAGE gels were
transferred on a PVDF membrane (Roth, pore size 0.45 µm) with a wet elec-
troblotting system (tank blotting) from Hoefer R©. Gels were blotted with
250mA for 1 h to 1.5 h in western blot buffer (1.1% (w/v) glycine, 0.24%
(w/v) Tris-Base, 25% (v/v) methanol, 0.01% (w/v) SDS). Membranes were
incubated in 10% skimmed milk suspended in 1×TBT buffer (10×TBT: 0.5M
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Tris-HCl pH 7.5, 1.5M NaCl, 1% (v/v) Tween 20) to reduce unspecific antibody
binding to the membranes. Next, membranes were incubated with the specific
antibody for the target protein in 5% skimmed milk in 1×TBT solution over
night at 4 ◦C. Membranes were washed 3 times with 1×TBT and 1 time with
1×PBS (137mM NaCl, 2.7mM KCl, 10.1mM Na2HPO4, 1.8mM KH2PO4).
Afterwards, membranes were incubated with a secondary antibody, coupled
to the horseradish peroxidase (HRP), which binds to the constant part of the
primary antibody, in 5% skimmed milk in 1×TBT for 1 h at room tempera-
ture. Membranes were again washed 3 times with 1×TBT and 1 time with
1×PBS. Detection of target proteins was facilitated by either using Western
Lightning R© Plus-ECL (PerkinElmer) with x-ray films (Biomax, Kodak R©) or
WesternSure R© ECL Substrate (LI-COR R©) with a LI-COR R© Odyssey system.
For protein quantification membranes were incubated with a fluorescently la-
beled secondary antibody and visualized with a LI-COR R© Odyssey system
or a Typhoon FLA9500 Biomolecular Imager (GE Healthcare). Signal inten-
sities were analyzed with the ImageStudioLite software (LI-COR R©) or the
ImageQuant TL software (GE Healthcare).
2.3.8 Purification of GST-fusion proteins from Escherichia
coli cells
GST epitope tagged proteins were expressed in Escherichia coli BL21 Rosetta
2 cells (Novagen), which were grown in TB medium (1.2% (w/v) BactoTM
tryptone, 2.4% (w/v) BactoTM yeast extract, 0.4% (v/v) glycerol, 17mM
KH2PO4, 72mM K2HPO4) at 37 ◦C and 150 rpm until they reached an OD600
of 1 to 1.5. Cultures were then cooled to 16 ◦C for 1 h and protein expression
was induced with 0.5mM IPTG (Roth) over night for 16 to 18 h. Cells were
harvested (Sorvall RC 6+, rotor FiberLite F10-4× 1000 LEX or rotor FiberLite
F10-6× 500y, 5000× g, 15min, 4 ◦C) and washed with cold ddH2O. Cells were
either stored at -80 ◦C or lyzed with high-pressure homogenization (EmulsiFlex-
C5, AVESTIN Europe GmbH) in 1×PBS buffer (137mM NaCl, 2.7mM KCl,
10.1mM Na2HPO4, 1.8mM KH2PO4) containing cOmpleteTM EDTA-free pro-
tease inhibitor (Sigma). The lysate was centrifuged (Sorvall RC 6+, SS34 rotor,
20,000× g, 30min, 4 ◦C) to remove remaining cell debris and the supernatant
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was incubated with an appropriate amount of Glutathione SepharoseTM 4Fast-
Flow for 2.5 h at 4 ◦C under constant stirring. Afterwards, the SepharoseTM was
washed 6 times (10 times the volume of the used SepharoseTM) with 1×PBS
buffer to remove unbound material and protease inhibitor. To elute the bound
protein without the GST-tag, the SepharoseTM was incubated with 3mL
1×PBS buffer and PreScission Protease (GE Healthcare) over night at 4 ◦C
under constant stirring. The supernatant was collected and the SepharoseTM
was washed another 2 times with 3mL 1×PBS buffer to gain high amounts
of cleaved protein. The supernatant was concentrated with Amicon R© Ultra
Centrifugal Filters (Merck Millipore) and stored at -80 ◦C. Doa10R variants
were additionally purified by gelfiltration with a Superdex 75 size exclusion
column (GE Healthcare) in 20mM HEPES buffer (pH7.5). Fractions were
analyzed by SDS-PAGE and Coomassie staining and were pooled according to
their content of pure Doa10R.
2.3.9 Purification of proteins with hexa histidine tags
from Escherichia coli cells
Hexa histidine epitope tagged proteins were expressed in Escherichia coli M15
(QIAGEN), which were grown in LB medium (1% (w/v) BactoTM tryptone,
0.5% (w/v) BactoTM yeast extract, 1% (w/v) NaCl) at 37 ◦C and 150 rpm until
they reached an OD600 of 1. Protein expression was induced with 0.5mM IPTG
(Roth) for 3 h at 37 ◦C and 150 rpm. Subsequently, cells were harvested (Sorvall
RC 6+, rotor FiberLite F10-4× 1000 LEX or rotor FiberLite F10-6× 500y,
5000× g, 15min, 4 ◦C). The pellet was washed with cold ddH2O and either
stored at -80 ◦C or lyzed with high-pressure homogenization (EmulsiFlex-C5,
AVESTIN Europe GmbH) in lysis buffer (50mM NaH2PO4, 300mM NaCl,
10mM imidazole, pH 7.5) containing cOmpleteTM EDTA-free protease inhibitor
(Sigma). The lysate was centrifuged (Sorvall RC 6+, SS34 rotor, 20,000× g,
30min, 4 ◦C) to remove remaining cell debris and the supernatant was incubated
with an appropriate amount of TALON R© Metall Affinity Resin (Clontech
Laboratories Inc.) for 2.5 h at 4 ◦C under constant stirring. Afterwards, the
resin was washed 3 times with cold wash buffer (50mM NaH2PO4, 300mM
NaCl, 20mM imidazole, pH7.5). The protein was eluted with elution buffer
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(50mM NaH2PO4, 300mM NaCl, 300mM imidazole, pH 7.5) and dialyzed over
night at 4 ◦C in dialysis buffer (50mM Tris-HCl pH7.5, 200mM NaCl, 5%
(v/v) glycerin). The protein solution was concentrated with Amicon R© Ultra
Centrifugal Filters (Merck Millipore) and stored at -80 ◦C.
2.3.10 Lowry protein assay for protein concentration de-
termination
Concentration of purified proteins was determined using the DC Protein Assay
(Bio-Rad), which is based on the protein detection method by Lowry [162].
A BSA concentration gradient served as calibration series for absorption at
750 nm to determine unknown protein concentrations.
2.3.11 Absorption measurements
Cell density of bacterial and yeast liquid cultures was determined by measuring
the absorption at 600 nm with a spectrometer (Ultrospec 3100 pro, Amersham
Bioscience). Protein or fluorophore concentrations were determined by measur-
ing the extinction at an appropriate wavelength (proteins: 280 nm, Alexa488:
490 nm) and by employing the Beer-Lambert law. Absorption measurements
were performed at room temperature with ultra micro cuvettes for the UV
spectrum (105.202-QS, Hellma) or disposable plastic cuvettes for the visible
spectrum (REF 67.742, Sarstedt).
2.3.12 Circular dichroism spectroscopy (CD)
CD measurements were performed with a Chirascan spectropolarimeter (Ap-
pliedPhotophysics). A total amount of 40 µg Doa10R variant was diluted in
CD buffer (100mM NaF, 10mM K2HPO4/KH2PO4, pH 8.5). Wavelength scans
were performed at 20 ◦C and were repeated 3 times for each sample. Emission
was recorded between 260 nm and 190 nm with a band-pass of 0.5 nm in a
quartz cuvette (Hellma) with a diameter of 0.1 cm. Wavelength scans with CD
buffer alone served as background control and were subtracted from all sample
measurements. Obtained values were corrected with the software provided
by dichroweb [163] by employing the following equation calculating the mean
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residue ellipticity:
[θ]MRE =
θ·100
c·d·N
[θ]MRE is the mean residue ellipticity with cm2dmol−1 as unit, θ are the
measured ellipticity values, c the protein concentration, d the path length of
the used cuvette and N the number of amino acid residues of the measured
protein.
2.3.13 Fluorescence labeling of Ub cysteine variants
The Ub variant S20C, carrying a single cysteine residue, was labeled with the
Alexa488 fluorophore connected to a C5 maleimide backbone (Life Technologies).
The thiol group of UbS20C was reduced with 120 nmol TCEP (Life Technologies)
in 400µL 1×PBS (137 mM NaCl, 2.7 mM KCl, 10.1 mM Na2HPO4, 1.8 mM
KH2PO4) for 10min at room temperature. Afterwards, the reaction mixture was
incubated with 4 times excess of fluorescent dye for 90min at room temperature
in the dark. The reaction was stopped with addition of β-mercaptoethanol
(final concentration 10mM). Excess amount of fluorescent dye and remaining
reduction reagent were removed with 2 size exclusion purification steps using
NAPTM -5 columns (GE Healthcare) with buffer containing 50mM Tris-HCl
(pH 8.0). The eluate was concentrated with Amicon R© Ultra Centrifugal Filters
(Merck Millipore). The labeling efficiency was determined by calculating
the ratio of fluorescent dye concentration (see section 2.3.11) and protein
concentration, which was determined with the Lowry protein assay (see section
2.3.10).
2.3.14 In vitro ubiquitylation reaction
Equal amounts (3.5 µM) of purified soluble Doa10 ligase components (Ubc6∆TM
varaints, Ubc7/Cue1∆TM, Doa10R variants) were incubated with 7.5 µM Ub
and 150 nM human E1 enzyme (Uba1) in ubiquitylation reaction buffer (50mM
HEPES pH7.5, 2.5mM magnesium acetate, 0.5mM DTT). The ubiquitylation
reaction was started with the addition of ATP (final concentration: 4mM,
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Sigma (A9187)) and incubated for 20min at 30 ◦C. Addition of 4× SDS sample
buffer (250mM Tris-HCl pH6.8, 40% (v/v) glycerol, 8% (w/v) SDS, 0.05%
(w/v) bromophenol blue, 100mM DTT) stopped the reaction and samples were
analyzed by SDS-PAGE, fluorescence scanning and immunoblotting. For time
course experiments: Samples for time point 0 were collected before the addition
of ATP. Ub lysine mutants UbK11R, UbK48R, UbK63R and UbK0 were purchased
from Boston Biochem Inc., and His6-Ub from ENZO R© life science GmbH.
2.3.15 Immunoprecipitation of Doa10R from in vitro ubiq-
uitylation reactions
The ubiquitylation reaction mixture was diluted with 15 volumes of IP buffer
(50mM Tris-HCl pH7.5, 150mM NaCl, 5mM EDTA, 1% (v/v) Triton X-100,
0.1% (w/v) SDS), which contained 15 µL ProteinA-SepharoseTM4FastFlow
(GE Healthcare) and 0.5 µL specific Doa10 antibody to precipitate Doa10R.
The suspension was incubated over night at 4 ◦C under constant stirring. In
a next step, SepharoseTM was washed 3 times with 500 µL IP buffer and the
SepharoseTM was incubated with 25 µL 4×SDS sample buffer (250mM Tris-
HCl pH6.8, 40% (v/v) glycerol, 8% (w/v) SDS, 0.05% (w/v) bromophenol
blue, 100mM DTT) to elute bound protein. Input samples were collected
before SepharoseTM was added to the reaction mixture. Samples were analyzed
by SDS-PAGE and immunoblotting.
2.3.16 Purification of ubiquitylated Ubc6∆TM from in
vitro assays
Ubc6∆TM was incubated with human E1 (Uba1) and N-terminal hexa histidine
tagged Ub as described in section 2.3.14 in a total reaction volume of 300 µL
for 16 h at 30 ◦C. The total reaction mixture was applied to a 1mL HisTrap
HP column (GE Healthcare). Bound proteins were extensively washed with
30 column volumes of wash buffer (50mM NaH2PO4, 300mM NaCl, 20mM im-
idazole, pH 7.5) and eluted with an imidazole gradient (20 to 300mM imidazole
in 30min, flow rate 1mL/min). Fractions were analyzed by SDS-PAGE and
Coomassie staining. Samples containing His6-Ub-Ubc6∆TM were pooled and
applied to a Superdex 200 size exclusion column (GE Healthcare) in gelfiltration
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buffer (20mM HEPES pH7.5, 150mM NaCl) to separate His6-Ub-Ubc6∆TM
from free His6-Ub. Fractions containing pure His6-Ub-Ubc6∆TM were pooled,
concentrated with Amicon R© Ultra Centrifugal Filters (Merck Millipore) and
stored at -80 ◦C.
2.3.17 Sample preparation for mass spectrometry analy-
sis
Mass spectrometry sample preparation was performed by Dr. Oliver Popp from
the mass spectrometry core facility (Dr. Gunnar Dittmar) of the Max Delbrück
Center for molecular medicine. Proteins separated on SDS-PAGE gels were
processed based on a protocol developed by Shevchenko et al. [164]. SDS-PAGE
gel pieces were washed with 50% ethanol in 50mM ammonium bicarbonate and
50mM ammonium bicarbonate in an alternating fashion. Disulfide bonds were
reduced with 2.5 pmol TCEP and alkylated with 12.5 pmol chloroacetamide for
30min at room temperature. Subsequently, samples were digested with 5 µg
sequencing grade Trypsin (Promega) for 10 h at room temperature. Originated
peptides were isolated with extraction buffer (80% (v/v) acetonitrile, 20mM
acetic acid) and dried with a SpeedVac (Savant). To preserve Ub ester bonds,
C18 stage tips [165] were purified under mild acidic conditions with 20mM
acetic acid and dried in a SpeedVac. Finally, peptides were dissolved in 3%
(v/v) acetonitrile in 20mM acetic acid.
2.3.18 Liquid chromatography tandem mass spectrome-
try (LC-MS/MS)
Mass spectrometry analysis was performed by Dr. Oliver Popp and Dr. Gunnar
Dittmar from the mass spectrometry core facility (Dr. Gunnar Dittmar) of the
Max Delbrück Center for molecular medicine. Samples were measured with
an LTQTM orbitrap VELOS mass spectrometer (Thermo Scientific) combined
with a Proxeon nano-LCTM system (Thermo Scientific). A nano-LC column
(0.074mm× 250mm, 3µm Reprosil C18, Dr. Maisch GmbH) was loaded with
5 µL sample and peptides were separated with a gradient (4 to 76% acetonitrile)
for 155min applying a flow rate of 0.25 µL/min. Peptides were ionized on the
proxeon and directly sprayed into the mass spectrometer. The acquisition
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was done at a resolution of 60,000 with a scan range from 200 to 1700m/z
in FTMS mode to select the top 20 peaks for CID fragmentation. MS/MS
scans were measured in IT mode with an isolation width of 2, the collision
energy was normalized to 40 eV and the dynamic exclusion was set to 60 s.
The MaxQuant software package version 1.5.2.8 was used for data analysis
[166]. Carbaminomethylation was set as a fixed modification and oxidized
methionine as well as acetylated amino acid termini as a variable one. To
identify ubiquitylation sites a variable modification was defined including a
monoisotopic mass-shift of 114.042927Da, which corresponds to an addition
of a double glycine (tryptic carboxy-terminal Ub fragment) on defined amino
acids (lysine, serine, threonine and cysteine residues). An FDR of 0.01 was
applied for peptides as well as proteins and the database search was performed
with Saccharomyces cerevisiae (S288c) Uniprot database (August 2014).
2.3.19 Quantification of Ub chains by mass spectrometry
Mass spectrometry analysis for Ub chain quantification was performed by Dr.
Oliver Popp and Dr. Gunnar Dittmar from the mass spectrometry core facility
(Dr. Gunnar Dittmar) of the Max Delbrück Center for molecular medicine. Ub
chains were quantified as published by Mirzaei et al. [167]. Heavily labeled
peptides (Spiketides, JPT peptide technology), which are designed to resemble
tryptic digested products of Ub branched peptides of certain chain linkages,
were added to ubiquitylation reactions. The reactions were digested with
endopeptidase LysC and Trypsin under denaturing conditions [168]. Peptides
were separated on a 20 cm in-house packed C18 column (75µm inner diameter,
3 µm Reprosil, Dr. Maisch GmbH) with a 5% to 50% acetonitrile gradient
applying a flow rate of 250 nL/min and directly sprayed into a Q-TRAP 5500
mass spectrometer (AB Sciex). Signals of branched peptides were recorded in
NRM mode and analyzed with the MultiQuant software package (AB Sciex).
Statistical analysis was performed with the R software package [169].
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2.4 Cytological methods
2.4.1 Cell culture of Escherichia coli
Bacterial cells were grown in liquid culture LB medium (1% (w/v) BactoTM
tryptone, 0.5% (w/v) BactoTM yeast extract, 1% (w/v)NaCl). Solid culture
medium was generated by adding 2% (w/v) agar-agar to the liquid LB medium.
For plasmid selection antibiotics were added to the medium (final concentration:
ampicillin 50 µg/mL, kanamycin 25 µg/mL).
2.4.2 Cell culture of Saccharomyces cerevisiae
Yeast cells were grown in either complete medium YPD (2% (w/v) BactoTM
peptone, 1% (w/v) BactoTM yeast extract, 2% (w/v) glucose, pH 5.5 adjusted
with HCl) or synthetic minimal medium SD (0.67% (w/v) yeast nitrogen base
without amino acids, 2% glucose, 20mg/L L-Histidine, 30mg/L L-Leucine,
30mg/L L-Lysine, 20mg/L L-Tryptophan, 20mg/L adenine sulfate, 20% uracil)
at 30 ◦C and 200 rpm. Solid culture medium was generated by adding 2% (w/v)
agar-agar to the liquid medium.
2.4.3 Yeast cell transformation with plasmid DNA
0.5 OD600 logarithmic growing yeast cells were centrifuged (2000× g, 2min) and
the pellet was suspended in 100µL 100mM lithium acetate and 1×TE buffer
(10mM Tris-HCl pH7.4, 1mM EDTA) containing 0.2 µg herring sperm DNA
and 0.5-1 µg/µL plasmid DNA. After addition of 500µL 40% PEG, 100mM
lithium acetate and 1×TE buffer, cells were incubated for 30min at 30 ◦C and
heat shocked at 42 ◦C for 15min. Cells were pelleted, resuspended in ddH2O
and platted on SD selection medium.
2.4.4 Sporulation and tetrad dissection
Haploid yeast strains with differing mating type were grown in 3mL YPD
medium over night. 500µL of each culture were combined in an Eppendorf tube
and incubated for 5 to 8 h at room temperature under constant stirring. Cell
aggregates were sedimented and platted on SD selection medium, which allowed
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only diploid cells with combined auxotrophy markers from both initial haploid
strains to grow. Diploid cells were grown over night at 30 ◦C in 3mL YPD
medium. 200 µL of this culture was used to inoculate 3mL of presporulation
medium (0.3% (w/v) BactoTM peptone, 0.8% (w/v) BactoTM yeast extract,
10% (w/v) glucose), which was cultured for 6 to 8 h at 30 ◦C and 200 rpm. 2mL
of this cell suspension were pelleted (2000× g, 2min), washed 2 times with 1mL
ddH2O and transferred into 3mL sporulation medium (0.1% (w/v) BactoTM
yeast extract, 0.05% (w/v) glucose, 1% (w/v) potassium acetate). Diploid
cells sporulated 2 to 4 days at 30 ◦C and 200 rpm and sporulation efficiency
was controlled with a light microscope (Zeiss). For separation of yeast tetrads,
1mL of the sporulation culture was centrifuged (2000× g, 2min) and the pellet
was resuspended in 1mL SED medium (18.2% (w/v) sorbitol, 25mM EDTA).
200µL of this suspension were mixed with DTT (final concentration 50mM)
and 200 µg Zymolyase (MB Biomedicals) and incubated at room temperature
for 20min to digest the ascus wall. Tetrads were dissected on a YPD plate using
a micromanipulator (Singer Instruments). Individual spores were analyzed by
replica plating on appropriate selection plates to determine their genotype.
2.4.5 Cycloheximide decay experiment
20OD600 logarithmic growing yeast cells (5OD600 for each time point of the
experiment) were harvested (2000× g, 2min) and the pellet was resuspended in
4.5mL SD medium. In a next step, 0.33mg/mL cycloheximide were added to
the cell suspension and immediately 1mL of the mixture was transferred into
an Eppendorf tube containing 0.5mL cold 50mM NaN3 and 1mM PMSF and
placed on ice. The rest of the sample was incubated at 30 ◦C and at the given
time points aliquots were removed and treated as described above. Aliquots
were centrifuged (20,000× g, 1min) and the cell pellet was suspended in 100 µL
lysis buffer (50mM Tris-HCl pH7.5, 1% (w/v) SDS, 1mM PMSF). After lysis
of the cells by vigorous shacking with glass beads, 100µL 2× SDS sample buffer
(135mM Tris-HCl pH6.8, 20% (v/v) glycerol, 4% (w/v) SDS, 0.05% (w/v)
bromophenol blue, 200mM DTT) were added and the lysate was incubated at
65 ◦C for 15min. Samples were centrifuged at 1000× g for 5min to separate
glass beads and cell debris from cell extract. The supernatant was collected
and analyzed by SDS-PAGE and immunoblotting (see section 2.3.5 and 2.3.7).
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3 | Results
3.1 Characterization of the ubiquitylation capac-
ity of Ubc6 and Ubc7
3.1.1 Ubc6 and Ubc7 are required for Doa10 dependent
substrate degradation in vivo
Genetic data imply that degradation of Doa10 client proteins depends on
activity of two E2 enzymes, Ubc6 and Ubc7 [136, 141, 170]. Deg1-GFP2 is a
model substrate of the Doa10 ligase and the influence of the different ligase
components on its proteolysis was investigated (figure 3.1). Deg1 is comprised
of a 68 amino acid long stretch of the Matα transcription factor, which confers
degradation through the Doa10 ligase pathway when fused to stable proteins
[133]. As shown in figure 3.1, degradation of Deg1-GFP2 was impaired in yeast
cells lacking Ubc6 and Doa10 or expressing a catalytically inactive Ubc7 variant
(Ubc7C89S). Disruption of the UBC6 gene in combination with an inactive Ubc7
mutant had no further impact on Deg1-GFP2 degradation, which implies that
both enzymes act in the same pathway. Obviously, the enzymatic activities of
Ubc6 and Ubc7 are required for Doa10-mediated substrate degradation.
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Figure 3.1 – Ubc6 and Ubc7 are both required for degradation of
Deg1-GFP2. (a) Cycloheximide decay assay monitoring turnover of Deg1-GFP2
in given yeast strains. Samples were analyzed by SDS-PAGE and immunoblotting
against GFP and Sec61 (loading control). (b) Quantified GFP signals of cyclohex-
imide experiments as exemplary presented in (a). Error bars represent the standard
deviation of mean from at least 3 independent experiments.
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3.1.2 Ubc6 and Ubc7 exhibit distinct ubiquitylation ac-
tivities in vitro
Figure 3.2 – Purified proteins for the
in vitro ubiquitylation assay. Exem-
plary presentation of purified proteins ex-
pressed in E.coli, separated on a SDS-
PAGE and stained with Coomassie. Sig-
nals corresponding to E1 enzyme (Uba1)
and UBE2J2∆TM are marked with an ar-
rowhead. Numbers on the right indicate
migration of standard proteins and their
corresponding molecular weight in kDa.
To study the catalytic propensities
of Ubc7 and Ubc6 in detail, an in
vitro ubiquitylation assay was estab-
lished based on a protocol developed
by Bagola et al. [142]. This approach
allows the detailed analysis of the
formed Ub reaction products with re-
gard to their abundance, length and
Ub linkage composition. Such in-
formation cannot be obtained by in
vivo studies due to the high amount
of Ub products within cells and the
disruptive activities of the deubiqui-
tylating system and the proteasome.
To this end, the cytoplasmatically
exposed parts of Ubc6 (Ubc6∆TM),
Cue1 (Cue1∆TM) as well as the
Doa10 RING domain (Doa10R) were
expressed in E.coli and purified. The
Ubc6∆TM and Cue1∆TM constructs lack the trans-membrane anchors, which
represent only minor parts of the full-length proteins. The Doa10R construct
is composed of the N-terminal region of the ligase that contains the RING
domain and neighboring elements until the first trans-membrane domain. How-
ever, it omits the 14 trans-membrane segments and the connecting ER-luminal
and cytoplasmatically exposed loops of Doa10. Thus, the Doa10R construct
represents only 10% of the total protein. The substrate recognition domains
of Doa10 are not identified yet, but it is speculated that they are not part of
Doa10R. Hence, incorporation of known substrates into the in vitro ubiquityla-
tion assay might prove to be difficult. Other cytoplasmic components of the
Doa10 ubiquitylation machinery as Ubc7, Uba1 (E1) and Ub were purified as
full-length proteins. The final products of the purified proteins are depicted in
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figure 3.2.
Figure 3.3 – Individual in vitro ubiquitylation properties of Ubc6∆TM and
Ubc7. (a, b) Time course experiments containing (a) Doa10R and Ubc7/Cue1∆TM
and (b) Doa10R and Ubc6∆TM. Samples were analyzed by SDS-PAGE and im-
munoblotting. Ub blots depict overall levels of Ub species including free unanchored
Ub chains as well as chains attached to substrate molecules. Asterisks indicate
cross-reaction signals of the corresponding antibody. The figure was adapted from
Weber et al. [155].
For the in vitro ubiquitylation assay equimolar amounts of the given proteins
were incubated as described in section 2.3.14. The reaction was started by
the addition of Ub variants and ATP. In a first setup each E2 enzymes was
separately incubated with Doa10R. Ubc7 in presence of its co-factor Cue1∆TM
and Doa10R readily catalyzed the formation of free unanchored Ub chains as
shown in figure 3.3 a. This is in agreement with results from Bagola et al. [142].
Notably, Ubc7 did not attach Ub molecules to itself or other proteins in the
assay. On the contrary, Ubc6 was barely able to form poly-Ub chains when
incubated with Doa10R (figure 3.3 b). Only tiny amounts of di or tri-Ub species
were detected in the Ub blots in figure 3.3 b. Strikingly, Ubc6∆TM attached
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single Ub moieties to itself and Doa10R in the course of the reaction. Both
in vitro ubiquitylation events can serve as reliable read-out of the enzymatic
properties of Ubc6∆TM. Ubc6 is a well-established substrate of the Doa10
ligase and its degradation depends on its own activity [152]. Furthermore,
RING domains, which interact with E2 enzymes [14], are known to serve as
artificial substrates in in vitro assays in the absence of other potential substrates
[105, 171].
Figure 3.4 – Ubc6∆TM and Ubc7 act in a consecutive manner on
Doa10R in vitro. (a) Time course experiment containing Doa10R, Ubc6∆TM
and Ubc7/Cue1∆TM. Samples were analyzed by SDS-PAGE and immunoblotting
with indicated antibodies. Ub blots depict overall levels of Ub species including free
unanchored Ub chains as well as chains attached to substrate proteins. Asterisks
mark cross-reaction signals of the corresponding antibody. (b) Ubc6∆L, a Ubc6
variant lacking linker and trans-membrane region, was incubated with Doa10R and
Ubc7/Cue1∆TM in varying combinations. Samples were analyzed by SDS-PAGE
and immunoblotting. The figure was adapted from Weber et al. [155].
Since Ubc6∆TM and Ubc7 display different enzymatic properties in the
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in vitro assay, it became interesting how both enzymes operate together at
the Doa10 RING domain. Consequently, the E2 enzymes were incubated
together with Doa10R in an experimental setup. Remarkably, Doa10R was
poly-ubiquitylated under those conditions over time (figure 3.4 a). This was
not observed when Doa10R was incubated with each E2 enzyme separately.
This indicates that a concerted action of both enzymes is required in vitro
to decorate Doa10R with poly-Ub chains. Poly-ubiquitylation of Ubc6∆TM
was not detected in the same experimental setup and was further studied as
described in section 3.1.7.
Figure 3.5 – Ub moieties are covalently attached to Doa10R. Doa10R was
immunoprecipitated from in vitro ubiquitylation reactions containing FLAG-Ub at
time points 0 and 20 min. Samples were analyzed by SDS-PAGE and immunoblotting
with specific antibodies for Doa10 and FLAG. The negative control in lane 5 did not
contain Doa10 antibody. Asterisks mark cross-reaction signals of the corresponding
antibody. The figure was adapted from Weber et al. [155].
To test whether the UBC core domain of Ubc6 is sufficient to mediate
Doa10R mono-ubiquitylation, a truncated Ubc6 variant (Ubc6∆L) was studied.
The Ubc6∆L construct lacks the linker and trans-membrane region of the wt
protein. The minimal Ubc6 construct was incubated with Doa10R in presence
and absence of Ubc7/Cue1∆TM (figure 3.4 b). Strikingly, the variant was still
capable to conjugate Ub molecules to Doa10R, which in turn initiated Doa10R
poly-ubiquitylation in presence of Ubc7/Cue1∆TM. However, Ubc6∆L did not
attach Ub moieties to itself in contrast to the Ubc6∆TM construct which still
contains the linker region (compare Ubc6 blots in figure 3.3 a,b). Thus, the
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ubiquitylation site of Ubc6 should be located within its linker region.
Immunoprecipitation (IP) experiments were performed to verify that Ub
moieties were indeed covalently conjugated to the Doa10R protein (figure 3.5).
For this purpose, Doa10R was incubated with N-terminal FLAG-tagged Ub
and precipitated at time points 0 and 20min from in vitro reactions. Poly-Ub
signals were only detected in IPs from reactions containing both E2 enzymes
Ubc6∆TM and Ubc7 after 20min. This experiment supports the necessity of
a collective action of Ubc6∆TM and Ubc7 to decorate Doa10R with poly-Ub
chains. Ubiquitylated full-length Doa10 was never detected when precipitated
from yeast cell extract (data not shown). Thus, it can be assumed that Doa10R
in vitro ubiquitylation is an artificial event, which takes place due to the absence
of other available substrates in the assay.
3.1.3 The enzymatic properties of Ubc6 are conserved in
human
Two orthologues of Ubc6 were identified in human: UBE2J1 and UBE2J2
[172, 173]. A multiple sequence alignment of all three proteins displays high
degree of similarity in their UBC domain located at the N-terminus (figure
3.6 a). The linker region between the UBC domain and the trans-membrane
anchor is less conserved. Especially UBE2J1 exhibits a much longer linker
region when compared to Ubc6 and UBE2J2. UBE2J2 is closer related to the
yeast protein and was chosen for further investigations in vitro. UBE2J2∆TM,
a truncated version lacking the trans-membrane anchor, was purified from
E.coli and assayed in in vitro ubiquitylation reactions (figure 3.6 b). The
human Ubc6 orthologue was able to conjugate mono-Ub to Doa10R as already
observed for Ubc6∆TM (section 3.1.1). The modification of Doa10R initiated
poly-ubiquitylation in presence of Ubc7/Cue1∆TM. In contrast to Ubc6∆TM,
UBE2J2∆TM did not mount Ub molecules on itself in the course of the reaction,
which is in line with previous observations [174]. Results from this experiment
clearly demonstrate that the enzymatic properties of E2 enzymes belonging to
the Ubc6 family are highly conserved in evolution.
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Figure 3.6 –UBE2J2∆TM mono-ubiquitylates Doa10R in vitro. (a) Clustal
Omega multiple sequence alignment [175] of Ubc6 and its human orthologues UBE2J1
and UBE2J2. The alignment was edited with Jalview and colored according to
BLOSUM62 (BLOcks SUbstitution Matrix) [176]. The trans-membrane region (TM)
and the active site cysteine (*) are highlighted. (b) UBE2J2∆TM-HA3 was incubated
with Doa10R in presence and absence of Ubc7/Cue1∆TM. Samples were analyzed by
SDS-PAGE and immunoblotting or fluorescence scanning. Asterisks mark unspecific
cross-reaction signals of the corresponding antibody. The figure was adapted from
Weber et al. [155]. 50
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3.1.4 Ubc6∆TM ubiquitylates Doa10R at several lysine
residues
Ubc6∆TM was shown to label Doa10R with mono-Ub moieties in vitro. Conse-
quently, the question was raised whether Ubc6 attaches the Ub molecules to a
specific lysine residue or to various sites within Doa10R. All nine lysine residues
in Doa10R were independently mutated to arginine (table 3.1) and tested in in
vitro ubiquitylation experiments to identify potential ubiquitylation sites.
Table 3.1 – List of analyzed Doa10R lysine mutants. MS - Mass spectrometry; ND -
not determined
Mutation Ubiquitylation Identified by MS pH sensitive
K18R yes no no
K57R yes yes no
K63R ND no ND
K77R yes no no
K83R yes yes no
K89R ND yes ND
K100R yes yes no
K110R yes no no
K119R yes yes no
Single lysine mutations did not result in diminished Doa10R in vitro ubiq-
uitylation as exemplary shown for the Doa10R variant K119R in figure 3.5 b.
Previously, it was reported that Ub moieties could be conjugated to hydrox-
ylated amino acids during protein quality control [75, 177]. Ester bonds, as
formed between the hydroxyl group of serine or threonine residues and the
C-terminus of Ub, are susceptible to elevated pH levels. To exclude that hydrox-
ylated amino acids were modified in Doa10R, samples from in vitro reactions
were incubated with 100mM NaOH (exemplary shown for Doa10RK119R in
figure 3.7 b). However, the Ub modification on Doa10R was not removed
upon elevation of pH levels (figure 3.7 b, lane 4 and 6). Thus, it can be
assumed that Doa10R ubiquitylation takes place mostly on lysine residues.
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In a next step, mass spectrometry analysis was employed to investigate if
multiple lysine residues in Doa10R are ubiquitylated by Ubc6∆TM (Mass
spectrometry measurements and analysis were performed by Oliver Popp and
Gunnar Dittmar). Several ubiquitylation sites were identified with this method
(table 3.1). Remarkably, all lysine residues clustered in the region of loop 2,
which encompasses the second zinc coordination site (figure 3.7 a). Supposedly,
Ubc6∆TM, when bound to the RING domain, is able to access this area.
Multiple mono-ubiquitylated Doa10R species were not detected in the course
of the experiments. This is most likely due to steric restrictions of the first
conjugated Ub moiety, which prevents further attachments of Ub moieties to
other sites. Summing up, Ubc6∆TM is able to ubiquitylate several lysine
residues within Doa10R, which indicates that the E2 is flexible in selecting
ubiquitylation sites in a target protein.
Figure 3.7 – Ubiquitylation sites in Doa10R. (a) In solution NMR structure of
the Doa10 RING domain covering amino acid residues from 19 to 101 (PDB ID: 2M6M)
[178]. Ubiquitylation sites, which were identified by mass spectrometry, are highlighted.
Structural depictions were prepared using PyMOL [31]. (b) Doa10RK119R was
incubated with Ubc6∆TM alone (lane 3 and 4) and with both enzymes Ubc6∆TM
and Ubc7/Cue1∆TM (lane 5 and 6). 100mM NaOH was added to samples to probe
for ubiquitylation of hydroxylated amino acids (lane 4 and 6). Negative controls
were incubated without ATP (lane 1) or inactive Ubc6C87S∆TM (lane 2). Samples
were analyzed by SDS-PAGE and immunoblotting against Doa10. Asterisks mark
unspecific cross-reaction signals of the antibody.
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3.1.5 Characterization of Ub chain types involved in
Doa10R in vitro ubiquitylation
Ub variants lacking individual lysine residues (UbK11R, UbK48R, UbK63R) were
incorporated into the experimental setup of the ubiquitylation assay to analyze
the Ub chain linkages involved in Doa10R poly-ubiquitylation. Ubc6∆TM was
able to attach all of these Ub variants equally well to itself and Doa10R (figure
3.8 a).
Figure 3.8 – Ubc6∆TM and Ubc7 decorate Doa10R with K48-linked poly-
Ub chains. (a) In vitro ubiquitylation reactions containing Ubc6∆TM, Doa10R
and different Ub variants (Ub, UbK11R, UbK48R, UbK63R). The negative control
(lane 1) was incubated with inactive Ubc6C87S∆TM. Samples were analyzed by SDS-
PAGE and immunoblotting with indicated antibodies. (b) In vitro ubiquitylation
reactions containing Ubc6∆TM, Ubc7/Cue1∆TM, Doa10R and different Ub vari-
ants (Ub, UbK11R, UbK48R, UbK63R). Samples were analyzed by SDS-PAGE and
immunoblotting with indicated antibodies. Asterisks mark cross-reaction signals of
the corresponding antibody. The figure was adapted from Weber et al. [155].
53
Results
Additionally, the formation of di-Ub species was observed in all reactions
containing active Ubc6∆TM. This suggests that Ubc6∆TM is able to conjugate
Ub donor moieties to different lysine residues within the Ub acceptor molecule.
In contrast, Ubc7 is known to exclusively synthesize K48-linked poly-Ub chains
[142]. This characteristic was confirmed for Doa10R in vitro poly-ubiquitylation
(figure 3.8 b). Ubc7 decorated Doa10R with poly-Ub chains in presence of
UbK11R and UbK63R to a similar extent as when incubated with wt Ub. The
mono-ubiquitylated form of Doa10R accumulated when UbK48R was incorpo-
rated in the in vitro reactions, because Ubc6∆TM conjugated single Ub moiety
to Doa10R but Ubc7 was not able to attach further Ub molecules to it due to
the absence of lysine 48 on the acceptor Ub.
Observations of Xu et al. suggest that Ubc6 favors the assembly of K11-linked
Ub chains [28]. The results shown in figure 3.8 a question these findings and thus
Ub-Ub conjugates generated by the E2 were analyzed by mass spectrometry.
Ub chain type quantification demonstrated that Ubc6∆TM forms very low
amounts of Ub chains in vitro (80 fmol in 20min) (figure 3.9). In contrast,
Ubc7 was shown to be much more active in synthesizing unanchored K48-linked
Ub chains (80 pmol in 15min) in a similar reaction setup [142]. Furthermore,
Ubc6∆TM mainly attached the donor Ub moiety to lysine 48 and 63 within the
Ub acceptor molecule (figure 3.9). Other linkage types were not identified in a
significant portion. Thus, Ubc6 is not specialized on poly-Ub chain formation
but rather on attaching single Ub moieties to lysine residues in client proteins.
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Figure 3.9 – Ubc6∆TM catalyzes minor amounts of K48- and K63-linked
Ub chains in vitro. Quantitative analysis of formed Ub linkages from in vitro
ubiquitylation experiments containing Ubc6∆TM or inactive Ubc6C87S∆TM with
mass spectrometry. Samples were measured in selected reaction monitoring (SRM)
and were compared to human Ub standards as described in detail in section 2.3.19.
Mass spectrometry measurements and analysis were performed by Oliver Popp and
Gunnar Dittmar.
To test how the attachment of Ub by Ubc6∆TM labels Doa10R for subse-
quent Ubc7-mediated poly-ubiquitylation, in vitro experiments were split into
two reactions to monitor the priming and elongation steps separately (figure
3.10). First, Doa10R was incubated with Ubc6∆TM-His6 and mutant Ub (either
UbK48R or UbK63R). In this reaction step Ubc6∆TM catalyzed the conjugation
of mono-Ub to Doa10R. Subsequently, Ubc6∆TM-His6 was removed from the
assay to prevent further modification of Doa10R. Next, mono-ubiquitylated
Doa10R was incubated with Ubc7/Cue1∆TM and excess amounts of wt Ub.
Doa10R was poly-ubiquitylated only when it had been labeled with UbK63R
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but not with UbK48R (figure 3.10). Summing up, this experiment demonstrates
that Ubc7 directly elongates the Ub moieties on Doa10R, which were attached
beforehand by Ubc6∆TM.
Figure 3.10 – Ubc7 attaches K48-linked Ub chains directly to Ub moieties
conjugated to Doa10R by Ubc6∆TM. Doa10R was incubated with UbK48R or
UbK63R in presence of Ubc6∆TM-His6 or Ubc6C87S∆TM-His6 or no E2. Subsequently,
Ubc6 variants were removed with TALONR© resin from the reactions and wt Ub
as well as Ubc7/Cue1∆TM were added. Samples were analyzed by SDS-PAGE
and immunoblotting. Asterisks indicate unspecific cross-reaction signals of the
corresponding antibody. Of note, commercially available UbK48R and UbK63R already
contained small amounts of di-Ub. The figure was adapted from Weber et al. [155].
Ub blots in figure 3.10 show that Ubc7 was active in all reactions since it
catalyzed the formation of unanchored Ub chains. However, overall levels of Ub
chains were reduced in reactions containing UbK48R, probably because residual
amounts of this Ub variant were incorporated into Ub conjugates. Furthermore,
Doa10R-Ub stimulated Ubc7 activity to a higher extent when compared to
unmodified Doa10R (compare lane 2 with lane 1 and 3 in Ub blots of the second
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incubation step in figure 3.10). This phenomenon was observed before for other
E2 enzymes due to binding of Ub to a backside interaction site in the UBC
domain, which further stimulates Ub chain elongation activity [179, 180].
3.1.6 Ubc6∆TM and Ubc7 interact with Doa10R through
a conserved binding site
It was shown that Doa10R ubiquitylation depends on the successive action of
Ubc6 and Ubc7. How both enzymes functionally interact with a single RING
domain remains elusive. Previous studies on the Anaphase Promoting Complex
(APC), which also engages two E2 enzymes during substrate ubiquitylation,
showed that initiating and elongating E2 enzymes interact differently with the
APC RING protein (APC11) [181]. The activity of the human chain initiating
E2 enzymes, UBCH5 and UBCH10, relies on a conserved binding site in the
RING domain. In contrast, the chain elongation activity of UBE2S requires
a different, non-conserved interaction site. To evaluate if Ubc6 and Ubc7
cooperate in a similar manner with Doa10R, a multiple sequence alignment
was conducted to identify conserved amino acids in APC11 and Doa10R (figure
3.11 a). Strikingly, the binding site of human APC11, which regulates chain
elongation, is not preserved in yeast APC11 or Doa10R (figure 3.11 a, green
dots). However, 3 amino acids, which are allocated to the chain initiating E2
binding site of APC11 are conserved in Doa10R (figure 3.11 a, red dots). All
three residues; isoleucine 41, arginine 43 and tryptophan 73, are part of the
major helix 1 and loop 1 of the Doa10 RING domain (figure 3.11 b). This area
is known to be a general docking site for E2 enzymes on E3 RING domains
[16].
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Figure 3.11 – Multiple sequence alignment of APC11 and Doa10R. (a)
Clustal Omega sequence alignment [175] of the Doa10 RING domain with human
and yeast APC11. The alignment was edited with Jalview and colored according
to BLOSUM62 (BLOcks SUbstitution Matrix) [176]. Conserved residues related
to canonical E2 binding are marked with red dots; non-conserved amino acids of
human APC11 allocated with Ub-chain elongation are marked with green dots. (b) In
solution NMR structure of the Doa10 RING domain (PDB ID 2M6M) with highlighted
amino acids, which are implicated in E2 binding [178]. Structural depictions were
prepared using PyMOL [31].
The conserved amino acids isoleucine 41, arginine 43 and tryptophan 73 were
substituted to alanine in Doa10R to test whether the putative E2 interaction site
regulates the enzymatic activities of Ubc6 and Ubc7. In a first reaction setup,
the impact of these mutations on Ubc7 activity was assessed (figure 3.12 a).
The catalysis of unanchored Ub-chains by Ubc7/Cue1∆TM is significantly
stimulated by addition of wt Doa10R. In contrast, Doa10RI41A did not enhance
Ubc7-mediated chain formation at all. Doa10RR43A and Doa10RW73A dis-
played an intermediate phenotype with Doa10RW73A enhancing Ubc7 activity
moderately better than Doa10RW73A. Ubc6∆TM activity was also signifi-
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cantly affected by the Doa10R variants as shown in figure 3.12 b. Doa10RI41A
completely abolished mono-ubiquitylation by Ubc6∆TM. Doa10RR43A was
mono-ubiquitylated to a similar extent as wt Doa10R and Doa10RW73A was
barely mono-ubiquitylated. Remarkably, Ubc6∆TM self-ubiquitylation was
unaffected by the Doa10R variants. This is in line with the observation that
Ubc6∆TM can modify itself in vitro independently of E3 activation (figure 3.15,
lane 3). Poly-ubiquitylation of the Doa10R variants was impaired in presence
of Ubc6∆TM and Ubc7 most likely because every mutation at least restricts
the enzymatic activity of one E2 (figure 3.12 c). Doa10RI41A affects both
enzymes strongly and therefore this variant was not modified in the course of
the reaction. Mono-ubiquitylated Doa10RR43A accumulated because it was not
efficiently modified by Ubc7 with poly-Ub chains. Doa10RW73A failed to recruit
Ubc6∆TM to initiate mono-ubiquitylation.
All Doa10R variants were analyzed by circular dichroism to exclude that
structural perturbations disturb the interplay between Doa10R and the E2
enzymes. They displayed similar CD spectra when compared to wt Doa10R
(figure 3.13), which resembled the typical spectra of an E3 RING domain
[182]. This indicates that the Doa10R variants did fold properly. Summing
up, the presented results suggest that both E2 enzymes functionally interact
with Doa10R through a conserved E2 binding site. Slight divergences could be
observed for the variants Doa10RR43A and Doa10RW73A, which propose that
Ubc6∆TM and Ubc7 engage in a distinct manner with Doa10R most likely to
fulfill their individual function during ubiquitylation.
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Figure 3.12 – Mutation of a conserved E2 binding site in Doa10R affects
the enzymatic activities of Ubc6∆TM and Ubc7. (a-c) In vitro ubiquitylation
reactions containing Doa10R variants (wt, Doa10RI41A, Doa10RR43A, Doa10RW73A)
with (a) Ubc7/Cue1∆TM, (b) Ubc6∆TM and (c) both E2 enzymes. The negative
control was incubated with inactive Ubc6C87S∆TM (b, lane 1). Samples were analyzed
by SDS-PAGE and immunoblotting. Asterisks mark cross-reaction signals of the cor-
responding antibody. (a) Quantification of unanchored Ub chain formation catalyzed
by Ubc7/Cue1∆TM normalized to basal reaction levels in absence of Doa10R. Error
bars represent standard deviation of mean from at least 3 independent experiments.
The figure was adapted from Weber et al. [155]. a.u. - arbitrary unit; w/o - without
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Questions were raised whether Ubc6 and Ubc7 compete for interaction
with Doa10R during ubiquitylation, because both E2 enzymes occupy the
same docking site. However, in vitro ubiquitylation experiments with different
Ubc6:Ubc7 ratios did not indicate that high amounts of Ubc6 can prevent
poly-ubiquitylation of Doa10R or vice versa (data not shown). Thus, it can be
speculated that even when one E2 enzymes is added in excess to the reaction,
the other one has still access to Doa10R. This is in line with observations,
which showed that E2 interactions with RING domains are extremely dynamic
and transient [13, 92].
Figure 3.13 –Circular dichroism spectra of Doa10R variants in comparison
to the wt protein. Wavelength scans were performed at 20 ◦C for Doa10RI41A,
Doa10RR43A, Doa10RW73A and wt Doa10R (for experimental details see section
2.3.12). The figure was adapted from Weber et al. [155].
3.1.7 Characterization of Ubc6 auto-ubiquitylation
Ubc6 itself is a target of the Doa10 ligase. Its turnover depends on its own
enzymatic activity and on that of Ubc7 (figure 3.14) [152]. In agreement with
these genetic data, Ubc6∆TM conjugated mono-Ub moieties to itself in the
course of in vitro ubiquitylation experiments (figure 3.3 b). It was shown earlier
that in vivo Ubc6 ubiquitylates itself in cis [152]. This was validated in vitro
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with an inactive His-tagged Ubc6∆TM variant (Ubc6C87S∆TM-His6) and an
active non-tagged Ubc6∆TM, which were incubated together in one reaction
set-up (figure 3.15). The active Ubc6∆TM variant was modified during the
reaction whereas the inactive variant was not (figure 3.15 lane 6 and 7). These
observations suggest that the Ubc6 molecule, which is ubiquitylated, initiates
its own turnover without the aid of another Ubc6 protein.
Figure 3.14 – Ubc6 is a Doa10 substrate. Quantification of Ubc6 signals from
cycloheximide experiments monitoring endogenous Ubc6 turnover in indicated yeast
strains. Error bars represent standard deviation of mean from at least 3 independent
experiments.
In in vitro experiments two modified Ubc6 species were detected, which could
account for mono- and di-ubiquitylated Ubc6 or a double mono-ubiquitylated
form (figure 3.15, Ubc6 blot). To assess whether Ubc6∆TM was ubiquitylated
at several sites with mono-Ub or at one position with di-Ub, a Ub variant
lacking all lysine residues was incorporated into the in vitro ubiquitylation
assay (UbK0) (figure 3.15, lane 9). This Ub variant allows single conjugation
through its C-terminus to target proteins but no chain formation through
internal lysine residues. Indeed, Ubc6∆TM readily attached this Ub variant to
itself. Furthermore, Ubc6∆TM-Ub2 conjugates were still generated in these
experiments, proposing that Ubc6∆TM is able to mono-ubiquitylate itself
simultaneously at several positions.
To exclude that Ubc6 attaches Ub molecules to the N-terminus of UbK0, the
experiment was repeated with N-terminal GST-tagged Ub (data not shown).
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Figure 3.15 – Characterization of the self-ubiquitylation capacity of
Ubc6∆TM in vitro. Ubc6 variants (Ubc6∆TM and Ubc6C87S∆TM-His6) were
incubated with Doa10R, Ubc7 and Cue1∆TM in different experimental setups. In
lane 9, UbK0 (Ub variant without lysine residues) was incorporated into the assay.
The negative control was incubated without ATP (lane 1). Samples were analyzed by
SDS-PAGE and immunoblotting. Asterisks mark non-specific cross-reaction signals
of the respective antibody.
Ubc6-Ub2 species were also observed in such reactions, which strengthen the
assumption that Ubc6 attaches several single Ub moieties to different sites
within itself. Interestingly, Ubc6∆TM conjugated Ub moieties to itself also
in absence of Doa10R to a similar extent as in presence of the RING domain
(compare lane 3 and 4 in figure 3.15). This suggests that self-modification of
Ubc6∆TM in vitro is not dependent on the stimulation by an E3 enzyme.
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Figure 3.16 –Ubc7 decorates Ubc6∆TM-Ub with poly-Ub chains. Enriched
Ubc6∆TM-Ub was incubated with Ubc7/Cue1∆TM and Doa10R (lane 3) to allow
its poly-ubiquitylation. The negative control was incubated without ATP (lane 1).
All reactions contained Doa10R.
Ubc6∆TM poly-ubiquitylation could not be detected in reactions containing
Ubc7 and Cue1∆TM (figure 3.15 lane 4 and figure 3.4). Even in experiments,
in which Ubc6∆TM was first mono-ubiquitylated and Ubc7/Cue1∆TM were
added thereafter, poly-Ub-Ubc6 conjugates were not observed (data not shown).
Possible explanations for this phenomenon could be the absence of the E2
recruitment platform of the Doa10 ligase. Consequently, Ubc6∆TM and
Ubc7 might not get into close proximity. This limitation would not account
for Doa10R poly-ubiquitylation since it was shown that both E2 enzymes
interact with the RING domain (section 3.1.6). Additionally, it could be
envisioned that Ub molecules attached to Ubc6∆TM are not accessible for
Ubc7/Cue1∆TM due to steric hindrances. To overcome these constrains,
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ubiquitylated Ubc6∆TM was purified in high quantities and subjected to
ubiquitylation reactions in excess (figure 3.16). Of note, not all unmodified
Ubc6∆TM could be separated from ubiquitylated species, because the protein
tented to stick to metal affinity raisin. However, experiments with enriched
Ub-Ubc6∆TM proteins showed tiny amounts of poly-ubiquitylated Ubc6∆TM
species in the presence of Ubc7/Cue1∆TM and Doa10R (figure 3.16, lane 3).
Thus it can be assumed that Ubc6∆TM poly-ubiquitylation takes place in the in
vitro ubiquitylation assay with low efficiency, which hinders detection. Doa10R
was mono-ubiquitylated in reactions containing high amounts of Ubc6∆TM-Ub
(figure 3.16, lane 2 and 5). This observation suggests that modified Ubc6∆TM
is still catalytically active. However, it cannot be excluded that low amounts
of unmodified Ubc6∆TM species account for the observed basal Ub priming
activity at Doa10R.
Figure 3.17 – Ubc6 is mono-ubiquitylated in vivo in dependency on its
own enzymatic activity. Ubc6 was precipitated from yeast cell extract devoid of
components of the Doa10 complex. All strains overexpressed wt Ub from plasmid.
Samples were analyzed by SDS-PAGE, immunoblotting and probed for Ubc6 and Ub.
The control strain in lane 1 did not contain UBC6.
To validate the in vitro findings on the self-ubiquitylation of Ubc6∆TM,
the protein was immunoprecipitated from cell extract prepared from strains,
which lacked components of the Doa10 ligase complex (figure 3.17). Ubc6
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was mono-ubiquitylated in wt, ∆ubc7 and ∆doa10 cells (Ubc6 blots in figure
3.17). In contrast, the active site mutant Ubc6C87S was not modified, which
is in line with observations from in vitro experiments (figure 3.16, lane 3).
Mono-ubiquitylated Ubc6 accumulated in ∆ubc7 and ∆doa10 yeast cells when
compared to the wt situation. This can be explained by the absence of Ubc7.
At an intact E3 ligase Ubc7 would act on these primed Ubc6 species and attach
poly-Ub chains to mono-ubiquitylated Ubc6. Ub blots of the IP experiment
are of poor quality most likely due to low abundance of poly-ubiquitylated
Ubc6. Nevertheless, Ubc6 appears to be poly-ubiquitylated in wt cells. In
contrast, Ubc6 seems to be modified to a significant lesser extent in cells lacking
components of the Doa10 ligase. Thus, the IP experiment of Ubc6 supports
the proposed model in which Ubc6 primes Doa10 target proteins and Ubc7
elongates these moieties with poly-Ub chains.
Summing up, it can be stated that mono-ubiquitylation of Ubc6∆TM is a
very robust event in vitro and in vivo, which does not depend on the presence of
the Doa10 ligase. This is most likely due to easily accessible ubiquitylation sites
close to the active center of Ubc6∆TM. Generally, this phenomenon has been
observed for several other E2 enzymes before [174]. On the contrary, Ubc6∆TM
poly-ubiquitylation is inefficient in vitro as well as in vivo in the absence of
the Doa10 ligase. This confirms the necessity of a recruitment platform, which
brings together target proteins and active components at the ligase to start the
ubiquitylation reaction.
3.1.8 Interaction of Ubc6 with the Doa10 RING domain
is mandatory for Doa10 substrate degradation
Investigation of Ubc6 auto-ubiquitylation showed that this phenomenon oc-
curs independently of the Doa10 ligase in vitro as well as in vivo (section
3.1.7). Whether Ubc6 is also able to mono-ubiquitylate Doa10 target proteins
autonomously of the Doa10 RING domain remains elusive. To address this
question, a Ubc6 variant, Ubc6Y66A, which does not interact with the Doa10
RING domain was characterized in detail. Tyrosine 66 is located in loop 4 of
the UBC domain of Ubc6 (figure 3.18 a). Substitution of aromatic amino acids
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in this area is known to interfere with E3 RING interaction [183, 184]. In vitro
experiments confirmed that the amino acid substitution from tyrosine to alanine
at position 66 abolished Doa10 mono-ubiquitylation (figure 3.18 b). In contrast,
Ubc6∆TM self-modification was only slightly reduced by the mutation, which
indicates that the amino acid substitution does not interfere with the enzymatic
activity of Ubc6∆TM.
Figure 3.18 – Ubc6Y66A∆TM does not attach Ub moieties to Doa10R in
vitro. (a) Structure of Ubc6 generated by homology modeling with SWISS-MODEL
covering amino acids from 5 to 164 [185]. Tyrosine 66 (yellow) and the active site
cysteine (red) are highlighted as well as the area, which is implicated in E3 interaction
(orange) [13, 186]. Structural depictions were prepared using PyMOL [31]. (b)
Ubc6Y66A∆TM and wt Ubc6∆TM were incubated with Doa10R, fluorescently labeled
Ub, E1 enzyme and Ubc7/Cue1∆TM where indicated. The negative control in
lane 1 did not contain ATP. Samples were analyzed by SDS-PAGE, immunoblotting
and fluorescence scanning. Asterisks mark non-specific cross-reaction signals of the
respective antibody.
Cycloheximide decay assays clearly demonstrated that turnover of Ubc6Y66A
is only modestly delayed when compared to wt Ubc6 (figure 3.19 c). How-
ever, proteolysis of the Doa10 model substrate Deg1-GFP2 was significantly
diminished when Ubc6Y66A was expressed (figure 3.19 d). Thus, interaction of
Ubc6 with the Doa10 RING domain is mandatory for degradation of Doa10
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clients. However, it remains unclear if the Doa10 RING domain activates the
ubiquitylation capacity of Ubc6 or if it positions the E2 favorably towards
substrates and initiates thereby the turnover of target proteins. Nevertheless,
the necessity for Doa10R binding might also prevent Ubc6 from ubiquitylating
randomly proteins in the ER membrane when it is not bound to the Doa10
ligase complex. Additionally, the presented data suggest that the self-initiated
turnover of Ubc6 represents an exception from general substrate ubiquitylation
at the ligase maybe due to the close proximity of available ubiquitylation sites
close to the active site.
Figure 3.19 – Expression of Ubc6Y66A diminishes proteolysis of the Doa10
model substrate Deg1-GFP2. (a,b) Cycloheximide decay assay monitoring
turnover of (a) Ubc6 and (b) Deg1-GFP2 in ∆ubc6 yeast cells, which harbored
plasmids expressing either wt Ubc6, Ubc6Y66A or Ubc6C87S (negative control). Sam-
ples were probed for Ubc6 and Cdc48 (loading control) or GFP and Sec61 (loading
control). Ubc6 signals in (a) were quantified to emphasize small differences between
degradation kinetics of the Ubc6 variants. Error bars represent standard deviation of
mean of 2 independent experiments.
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3.2 Investigation of non-canonical ubiquitylation
events catalyzed by Ubc6
3.2.1 Identification of ubiquitylated lysine residues within
Ubc6∆TM
As demonstrated before, Ubc6 itself is a short-lived protein, which is degraded
in dependency on the Doa10 ligase components (figure 3.14). On the one hand,
Ubc6 turnover could be a regulatory element to control Doa10 function. On
the other hand, it might be a coincidental event, which happens due to the
robust self-ubiquitylation activity of Ubc6, which starts the ubiquitylation
cascade at the ligase. To distinguish between these two scenarios, it was the
aim to generate and subsequently characterize a stable Ubc6 variant. For this
purpose, ubiquitylation sites within Ubc6 were determined to mutate them and
thereby preventing Ubc6 turnover. The linker region of Ubc6 was reported to
be required for its continuous turnover [152]. This observation was supported by
in vitro experiments showing that a truncated Ubc6 variant Ubc6∆L, lacking
the linker region, is not ubiquitylated in vitro (figure 3.4 b). Thus, it seems
plausible that Ub acceptor sites are located within this linker area. Ubc6
contains around 11 lysine residues in the region connecting the catalytically
core domain and the trans-membrane anchor (figure 3.20 a). Hence, mass
spectrometry analysis was employed to identify potential ubiquitylation sites in
Ubc6∆TM. In a first analysis two ubiquitylated lysine residues at position 133
and 151 were detected. To test their relevance in vitro and in vivo these residues
were mutated to arginine. Because lysine 133 is directly neighbored by another
lysine residue at position 132, both amino acids were exchanged to ensure the
complete disruption of this ubiquitylation site. However, cycloheximide decay
experiments showed that the individual as well as the combined mutations
(Ubc6∆K3) did not diminish Ubc6 proteolysis (figure 3.20 b).
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Figure 3.20 – Mutation of several lysine residues in the linker region of
Ubc6 does not affect its proteolysis. (a) Protein sequence of Ubc6 with high-
lighted catalytically core domain (UBC), the linker region (Linker) and the trans-
membrane anchor (TM). Lysine residues, which were substituted to arginine, are
depicted in green. (b,c) Cycloheximide decay experiments monitoring (b) Ubc6 or
(c) Deg1-GFP2 turnover in yeast strains expressing differing Ubc6 variants (wt Ubc6,
Ubc6K132R,K133R, Ubc6K151R, Ubc6K132R,K133R,K151R (Ubc6∆K3) and Ubc6∆K11).
The mutant Ubc6∆K11 harbors lysine to arginine substitutions at following positions:
132, 133, 151, 167, 169, 188, 191, 193, 221, 222 and 225. Ubc6 turnover was addition-
ally analyzed in yeast cells devoid of DOA10. Samples were analyzed by SDS-PAGE
and immunoblotting and probed for Ubc6 or GFP and Sec61 (loading control).
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The stability of the Ubc6 mutants was tested in yeast strain deleted for
DOA10. All Ubc6 variants displayed diminished proteolysis under these condi-
tions, which indicates that they are still degraded through the Doa10 pathway.
This was supported by cycloheximide decay assays monitoring the turnover of
the Doa10 model substrate Deg1-GFP2, which did not display any perturbations
due to the expression of the different Ubc6 variants (figure 3.20 c). Additionally,
in vitro ubiquitylation experiments demonstrated that all Ubc6∆TM variants
were similarly ubiquitylated when compared to wt Ubc6∆TM (data not shown).
Summing up, the experiments suggest that both identified ubiquitylation sites
do not substantially contribute to Ubc6 turnover. Additionally, the observa-
tions provide further evidence for Ubc6 being extremely versatile in choosing
ubiquitylation sites within its linker region. This phenomenon was already ob-
served for Doa10R in vitro ubiquitylation, where Ubc6 did not target a specific
lysine residue (section 3.1.4). Further mass spectrometric analysis identified
additional ubiquitylation sites in Ubc6∆TM. Mutation of these sites alone as
well as combinations of these mutations did not impact Ubc6 turnover (data
not shown). Even substitution of all 11 lysine residues to arginine in the linker
area (Ubc6∆K11) had no influence on the half-life of the protein in vivo (figure
3.20 b). However, steady-state levels of this Ubc6 variant were diminished,
which explains a slower turnover of Deg1-GFP2 in these cells (figure 3.20 c).
Ubc6∆K11 is still degraded by the Doa10 pathway because it accumulates
in ∆doa10 yeast cells, which suggests that this variant is at least partially active.
For further characterization, Ubc6∆K11∆TM was expressed in E.coli and
purified. In vitro ubiquitylation experiments showed that the variant still
auto-ubiquitylated itself to a similar extent as wt Ubc6∆TM (figure 3.21).
The variant mono-ubiquitylated Doa10R only moderately. The reasons for
this behavior are unknown. However, it can be speculated that the severe
manipulation of the Ubc6 linker region might affect the interaction with Doa10R.
To test if the prominent ubiquitylation on Ubc6∆TM is located on lysine
residues or if it involves the modification of other amino acids such as serine
or threonine residues, samples were incubated with 100mM NaOH. Oxyester
linkages between the C-terminus of Ub and the hydroxyl-group of amino acid are
susceptible to changes in the pH [177]. In contrast, isopeptide linkages between
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the ε-amino group of a lysine residue and the carboxyl-group of the C-terminus
of Ub are not cleaved upon elevation of pH levels. Additionally, ubiquitylation
was also reported to occur on cysteine residues. Thioester linkages between
cysteine residues and the C-terminus of Ub can be cleaved by adding reducing
agents as β-mercaptoethanol [59].
Figure 3.21 – Ubc6∆TM is ubiquitylated at hydroxylated amino acids in
vitro. Ubc6∆K11∆TM and wt Ubc6∆TM were incubated with Doa10R, fluorescently
labeled Ub and E1 enzyme. Samples were incubated with 100mM NaOH when
indicated. The sample in lane 1 did not contain ATP (negative control). Asterisks
mark cross-reaction signals of the corresponding antibody.
Surprisingly, most of the ubiquitylation signals on Ubc6∆K11∆TM and
Ubc6∆TM were removed upon treatment with NaOH. This observation indi-
cates that Ubc6∆TM is primarily ubiquitylated at serine or threonine residues
but not on lysine residues. The ubiquitylation signal on Ubc6∆TM was not
cleaved off upon the addition of β-mercaptoethanol, which argues against
cysteine ubiquitylation of Ubc6∆TM in vitro (data not shown). However,
the general analysis of reaction products was conducted in presence of the
reducing agent DTT, which might already remove such linkages. Thus, further
experiments are required to fully exclude ubiquitylation of cysteine residues
within Ubc6∆TM. Ubiquitylation of lysine residues seems to play a minor role
in Ubc6∆TM self-modification in vitro. This becomes evident by the small
amount of Ubc6∆TM-Ub, which is detectable after the NaOH treatment. Of
note, Ub was fully removed from Ubc6∆K11∆TM in NaOH treated samples,
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which demonstrates that some lysine residues are modified within the linker
region. These results imply that Ubc6 is able to target various sites within its
linker area. Additionally, the E2 does not only mount Ub on lysine residues
but also on hydroxylated amino acids.
3.2.2 Ubc6∆TM is ubiquitylated at hydroxylated amino
acids in vitro
Experiments presented in the previous section 3.2.1 gave some evidence for
ubiquitylation of serine or threonine residues on Ubc6∆TM in vitro. However,
dissociation of putative oxyester linkages with high pH is by no means a di-
rect proof for such an activity. To determine if Ubc6 is able to ubiquitylate
hydroxylated amino acids, mass spectrometry analysis was employed, using
an adapted protocol to preserve oxyester linkages (sections 2.3.17 and 2.3.18).
Several amino acids including lysine but also serine and threonine residues were
identified as potential ubiquitylation sites (table 3.2).
Table 3.2 – List of potentially ubiquitylated amino acids within Ubc6∆TM identified
by MS.
Amino acid Position Unambiguous
identification
Experimentally
investigated
Lysine 15 no no
Lysine 67 no no
Lysine 151 no yes
Lysine 169 no yes
Lysine 188 no yes
Lysine 193 yes yes
Serine 139 no no
Serine 196 yes yes
Threonine 139 no no
Threonine 164 no no
Threonine 178 no no
Threonine 187 no no
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Interestingly, the majority of these residues clustered in the linker region, the
putative ubiquitylation "hot spot" of Ubc6. However, most of these positions
could not be definitely identified as Ub acceptor sites in the mass spectrometric
analysis because the corresponding fragments of the tryptic peptides were
not detected. Nevertheless it can be assumed that some of them are indeed
ubiquitylated. The ubiquitylation of one serine residue was clearly assigned to
position 196 in Ubc6 with mass spectrometry (figure 3.22 a,b).
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Figure 3.22 – Ubc6∆TM is ubiquitylated at serine 196. (a) Schematic repre-
sentation of the chemical structure of an oxyester bond between the C-terminus of a
Ub molecule and a hydroxyl-group of the serine side chain in Ubc6 at position 196.
(b) Ubc6∆TM was incubated with E1, Ub and ATP for 20min and subsequently
separated on SDS-PAGE gels and Commassie stained. Ubc6∆TM-Ub was isolated
and processed as described in section 2.3.17. The b and γ-fragmentation pattern of
the tryptic peptide covering amino acids from 194 to 206 shows a Gly-Gly site on
serine 196 (page 75). Mass spectrometry measurements and analysis were performed
by Oliver Popp and Gunnar Dittmar. The figure was adapted from Weber et al.
[155].
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To determine any relevance of serine 196 ubiquitylation for Ubc6 function or
turnover, it was substituted to alanine and the resulting Ubc6 variant was ana-
lyzed in vitro and in vivo. Remarkably, Ubc6S196A∆TM was significantly less
ubiquitylated in vitro when compared to wt Ubc6∆TM (figure 3.23). Still, the
Ubc6S196A∆TM-Ub signal decreased slightly upon NaOH treatment, which sug-
gests that serine 196 is the most important but not the only hydroxylated amino
acid in Ubc6 that can be ubiquitylated. Ubc6S196A∆TM mono-ubiquitylated
Doa10R to a similar extent as wt Ubc6∆TM, which demonstrates that the
amino acid substitution does not interfere with the enzymatic activity of the
E2.
Figure 3.23 – Mutation of serine 196 significantly reduces Ubc6 auto-
ubiquitylation in vitro. wt Ubc6 and Ubc6S196A∆TM were incubated with
Doa10R, fluorescently labeled Ub and E1 as well as Ubc7/Cue1∆TM (lane 7 and
8). 100mM NaOH was added when indicated (lane 4, 6 and 8). Negative controls
are displayed in lane 1 and 2, which were devoid of ATP. Asterisks mark non-specific
cross-reaction signals of the respective antibody. The figure was adapted from Weber
et al. [155].
Doa10R ubiquitylation was preserved upon addition of NaOH (figure 3.23
lane 4, 6 and 8) as well as unanchored K48-linked Ub chains formed by Ubc7
(figure 3.23, lane 8). This shows that the elevated pH levels do not dissipate
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lysine-linked Ub conjugates in the in vitro assay.
To test if Ubc7 is able to elongate Ub moieties, which are attached to hydrox-
ylated amino acids, wt Ubc6∆TM-Ub and Ubc6S196A∆TM-Ub conjugates were
purified and incubated with Ubc7 and Cue1∆TM in presence of Ub and E1
enzyme. Ub-Ubc6∆TM as well as Ub-Ubc6S196A∆TM were poly-ubiquitylated
by Ubc7 in the course of this reaction (figure 3.24, lane 3 and 7). However,
poly-Ub chains showed an increased sensitivity to elevated pH levels when
they were attached to wt Ubc6∆TM as when conjugated to the mutant (figure
3.24, lane 4 and 8). Thus, it can be assumed that in wt Ubc6∆TM serine 196
is predominantly mono-ubiquitylated and serves as template for subsequent
Ub-chain elongation by Ubc7. In absence of serine 196 other amino acids
especially lysine residues are mono-ubiquitylated and thus elevated pH level
do not affect these modifications. However, in vivo experiments are absolutely
required to confirm these in vitro observations to ensure that no artifacts are
analyzed in the in vitro setup.
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Figure 3.24 – Ubc7 is able to conjugate Ub chains to Ub moieties
attached to hydroxylated amino acids. Enriched wt Ubc6∆TM-Ub and
Ubc6S196A∆TM-Ub species were incubated with Ubc7/Cue1∆TM to initiate their
poly-ubiquitylation (lane 3, 4 and lane 7, 8). Samples were incubated with 100mM
NaOH where indicated (lane 2, 4 and lane 6, 8). SDS-PAGE and immunoblotting
were applied. Two images of the same Ubc6 blot are presented with differences
in contrast and brightness to emphasize signals for weak Ubc6 poly-ubiquitylation.
Asterisks mark non-specific cross-reaction signals of the respective antibody.
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3.2.3 Ubc6 catalyzes non-conventional ubiquitylation events
in vivo
In vitro experiments implicate non-canonical ubiquitylation of hydroxylated
amino acids by Ubc6. Cycloheximide decay assays were employed to assess
the impact of the serine to alanine substitution at position 196 on Ubc6
degradation in vivo (figure 3.25 a,b). The turnover of the Ubc6S196A variant
was not diminished when compared to wt Ubc6 (figure 3.25 a).
Figure 3.25 – Ubc6S196A does not display a degradation defect in vivo.
(a,b) Cycloheximide decay assays monitoring the turnover of (a) Ubc6 and (b)
Deg1-GFP2 in ∆ubc6 yeast cells expressing different Ubc6 variants (wt Ubc6,
Ubc6C87S and Ubc6S196A) from plasmid. Inactive Ubc6 (Ubc6C87S) served as negative
control. Samples were probed for Ubc6 or GFP and Sec61 (loading control).(c) Total
cell extract was prepared from ∆ubc6 yeast cells with and without disruption of the
DOA10 gene, which carried plasmids encoding for wt Ubc6 or Ubc6S196A as well as
an overexpression plasmid for wt Ub. Samples were incubated with 150mM NaOH
when indicated and were probed for Ubc6. The figure was adapted from Weber et al.
[155].
Consequently, degradation of the Doa10 model substrate Deg1-GFP2 was
neither affected (figure 3.25 b). These observations suggest that serine 196 is
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not solely responsible for the initiation of Ubc6 degradation in vivo. It can
be assumed that other amino acids in the linker are ubiquitylated, which then
serve as priming template for Ubc7. This is in agreement with previous studies
on the non-secreted immunoglobulin light chain NS-1, whose turnover was
only efficiently diminished by mutating all putative ubiquitylation sites within
the protein [75]. To study the relevance of non-conventional ubiquitylation
events in vivo, ubiquitylation of wt Ubc6 and Ubc6S196A was determined when
subjected to elevated pH levels (figure 3.25 c). In absence of Doa10, both Ubc6
variants were mono-ubiquitylated, but Ubc6S196A to a lesser extent as the wt
protein. This is in line with results from in vitro experiments presented in
figure 3.23. Both Ub modifications were susceptible to elevated pH levels, which
implies that non-canonical ubiquitylation of hydroxylated amino acids plays a
major role in Ubc6 proteolysis. Summing up, serine 196 indeed participates in
Ubc6 ubiquitylation in vivo, however it is not the only amino acid, which can
serve as priming site for poly-ubiquitylation. This observation adds another
evidence for the flexibility of Ubc6 in choosing ubiquitylation sites in client
proteins.
3.2.4 Ubc6 facilitates degradation of the Doa10 substrate
Sbh2 in absence of accessible lysine residues
Sbh2 is a tail-anchored protein of the endoplasmic reticulum (figure 3.26 a),
which in absence of its binding partner Ssh1 is degraded via the Doa10 ligase
complex (figure 3.26 b,c) [187]. Interestingly, turnover of Sbh2 was only mildly
affected in cells devoid of UBC6 but strongly affected in ∆ubc7 strains [187].
This suggests, that Ubc7 is able to initiate proteolysis of this protein, through
in a less efficient manner as Ubc6. Sbh2 exhibits a prominent cluster of lysine
residues in its cytosolic domain (figure 3.26 a, red dots). Interestingly, a Sbh2
variant Sbh2∆4K, which harbors amino acid substitutions to arginine at these
positions, was still degraded with the same half-life as the wt protein. However,
the turnover of Sbh2∆4K depends strongly on Ubc6 (figure 3.26 b,d). In
contrast, mutation of lysine 48 in Sbh2, which is located downstream from the
lysine cluster, did not interfere with Sbh2 proteolysis (data not shown).
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Figure 3.26 – Sbh2 turnover can be driven into Ubc6 dependency by mu-
tating cytosolic lysine residues. (a) Sequence of Sbh2 with highlighted lysine
residues at position 15, 23, 25, 28, 48 and 83 (green). Lysine residues substituted to
arginine in the Sbh2 variant Sbh2∆4K are marked with a red dot. (b) Cycloheximide
decay assay monitoring turnover of wt Sbh2 and Sbh2∆4K in yeast cells devoid of
SSH1 combined with different gene knockouts of Doa10 ligase components. (c,d)
Quantification of Sbh2 signals from cycloheximide experiments of (c) wt Sbh2 and
(d) Sbh2∆4K as exemplary presented in (b). Error bars represent standard deviation
of mean of at least 3 independent experiments. The figure was adapted from Weber
et al. [155].
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Immunoprecipitation of FLAG-tagged Sbh2 variants demonstrates that wt
Sbh2 is significantly stronger ubiquitylated in ∆ubc6 cells when compared to
Sbh2∆4K (figure 3.27). Thus, it can be assumed that Ubc7 is able to attach
Ub moieties directly to wt Sbh2 to one or several sites in its cytosolic lysine
cluster.
Figure 3.27 – Sbh2 is ubiquitylated in yeast cells devoid of UBC6. FLAG-
tagged wt Sbh2 and Sbh2∆4K were immunoprecipitated from yeast cell extract
prepared from strains devoid of proteins of the Doa10 ligase complex as well as SSH1.
All cells were overexpressing Myc-tagged Ub from plasmid. Additionally, all strains
harbored a proteasomal mutant rpt4R to diminish proteolytic turnover, which in
turn enriched ubiquitylated protein species within the cells. Samples were analyzed
by SDS-PAGE and immunoblotting and probed for Myc and FLAG. The figure was
adapted from Weber et al. [155].
Ubc6 seems to be flexible in choosing ubiquitylation sites in Sbh2, since
Sbh2∆4K, which lacks cytosolic lysine residues, was degraded with a similar
kinetic as wt Sbh2 (figure 3.26). To test whether Ubc6 ubiquitylates hydroxy-
lated amino acids in absence of suitable lysine residues, FLAG-tagged wt Sbh2
and Sbh2∆4K were immunoprecipitated and the samples were treated with
NaOH prior to loading on SDS-gels. As expected, ubiquitylation of Sbh2∆4K
was removed upon elevation of pH levels, whereas ubiquitylated species of
wt Sbh2 were stable under these conditions (figure 3.28). This suggests that
Sbh2∆4K is ubiquitylated at hydroxylated amino acids. Ubiquitylation signals
for mutant Sbh2∆4K were weaker when compared to wt Sbh2 (compare lane 2
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and 3 in figure 3.28). Either Sbh2∆4K is less ubiquitylated as the wt protein
or ubiquitylated material is lost during the experimental procedure due to
the fragile nature of the oxyester bonds between substrate and Ub moieties.
The second assumption would also explain why Ubc6 ubiquitylation, which
mostly depends on a non-canonical serine ubiquitylation, is hardly detectable
in immunoprecipitation experiments (figure 3.17). Summing up, it becomes
evident that Ubc6 ubiquitylates hydroxylated amino acids in absence of accessi-
ble lysine residues, which ensures efficient degradation of Doa10 client proteins
during protein quality control.
Figure 3.28 – Ubiquitylation of Sbh2∆4K is susceptible to elevated pH
levels. FLAG-tagged wt Sbh2 and Sbh2∆4K were immunoprecipitated from cell
extract prepared from yeast strains devoid of SSH1. All strains overexpressed Myc-
tagged Ub from plasmid. Samples were treated with 150mM NaOH when indicated.
Samples generated from strains, which did not contain FLAG-tagged protein, served
as negative control (lane 1 and 4). The here presented experiment was performed by
Ernst Jarosch. The figure was adapted from Weber et al. [155].
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3.3 Characterization of the Ubc6 overexpression
phenotype
3.3.1 Ubc6 overexpression impairs Doa10 dependent sub-
strate degradation
Initially, the Ub conjugating enzyme Ubc6 was identified as a high copy number
suppressor of the temperature sensitive growth phenotype in yeast strains that
harbor the sec61-2 mutation [151]. The Sec61 mutant protein is selectively
degraded at elevated temperatures, which results in reduced protein levels
[188, 189]. Because Sec61 is part of the essential protein translocation apparatus
of the ER, these cells fail to grow under these conditions [157]. Deletion of
components of either the Doa10 ligase or the Hrd1 ligase can partially rescue
growth due to a diminished degradation of the mutant protein, which results
in elevated protein levels within the cells (figure 3.29) [189].
Figure 3.29 – The sec61-2 growth phenotype is suppressed in cells devoid
of UBC6 as well as in cells overexpressing the E2 enzyme. Suppression of
the sec61-2 growth defect in yeast strains carrying gene disruptions of Doa10 and
Hrd1 ligase components. UBC6 overexpression was induced with a high copy plasmid
encoding for Ubc6 under its endogenous promoter. All other strains were transformed
with an empty vector control. Cells were plated on appropriate selection medium
and incubated at 30 ◦C and 37 ◦C.
Because the Hrd1 and the Doa10 pathway are both involved in the degrada-
tion of Sec61-2, deletion of UBC7 showed a similar degree of suppression as the
double knockout of the ligases (figure 3.29). Remarkably, the overproduction
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of Ubc6 suppressed the sec61-2 phenotype to a similar extent as a UBC6 or
DOA10 loss-of-function mutant (figure 3.29) [151]. Thus, it can be assumed
that elevated Ubc6 protein levels negatively impact the proteolysis of Doa10
client proteins. To evaluate if UBC6 overexpression generally affects Doa10
substrate turnover, cycloheximide decay assays were performed. Degradation of
Ubc6 was impaired when overexpressed (figure 3.30 a,b). Since the E2 enzymes
Ubc6 and Ubc7 act at the same ligase, elevated Ubc6 levels might displace Ubc7
from the complex and thereby affecting Doa10 dependent protein degradation.
However, the observed UBC6 overexpression phenotype could not be rescued by
the simultaneous overproduction of Ubc7 and Cue1. Further elevation of Doa10
protein levels also did not rescue the phenotype. These observations suggest
that UBC6 overexpression has a dominant negative effect on Doa10-mediated
protein turnover. On the contrary, elevated levels of Ubc7 and Cue1 did not
display any influence on endogenous Ubc6 turnover. Notably, overproduction
of a Ubc6 variant, which lacked its catalytic core domain (Ubc6∆UBC) but
was stably recruited to the Doa10 ligase (figure 3.34 lane 6), did not result in
a diminished proteolysis of endogenous Ubc6. This shows that the dominant
negative effect of UBC6 overexpression depends on its enzymatic activity.
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Figure 3.30 – Proteolysis of Ubc6 is diminished when the protein is over-
produced. (a) Cycloheximide decay assay monitoring Ubc6 turnover under wt and
different overexpression conditions of Doa10 ligase components as well as a Ubc6
variant lacking the UBC core domain (Ubc6∆UBC). Increased expression levels of
Ubc6 variants, Ubc7 and Cue1 were induced with high copy plasmids. Elevated
Doa10 protein levels were generated by substitution of the Doa10 promoter with
the TEF-promoter. Samples were analyzed by SDS-PAGE and immunoblotting and
probed for Ubc6 and Sec61 (loading control). Overexpression of Doa10 components
was validated by immunoblotting (data not shown). (b) Quantification of Ubc6 sig-
nals from cycloheximide experiments as exemplary shown in (a). Error bars represent
standard deviation of mean from at least 3 independent experiments.
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The turnover of Deg1-GFP2 was monitored to investigate the impact of
UBC6 overexpression on other Doa10 substrates (figure 3.31 a,b). Deg1-GFP2
proteolysis was significantly diminished when Ubc6 protein levels were elevated,
despite the parallel overexpression of other Doa10 ligase components. Again,
the overproduction of a truncated Ubc6 variant lacking the UBC core domain
(Ubc6∆UBC) did not influence the degradation of Deg1-GFP2. Of note,
quantification of GFP signals from cycloheximide experiments indicates that the
UBC6 overexpression effects on Deg1-GFP2 turnover are rather variable (huge
standard deviation of mean for different time points). Generally, expression
levels of proteins induced by 2-micron plasmids are rather fluctuating, possibly
because of variations in the copy number of plasmids within individual cells
[190]. Hence, Ubc6 levels might vary between independent experiments, which
results in a differing level of suppression of the Deg1-GFP2 proteolysis.
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Figure 3.31 – Increased Ubc6 protein levels impair degradation of
Deg1-GFP2. (a) Cycloheximide decay assay monitoring Deg1-GFP2 turnover under
wt and different overexpression conditions of Doa10 ligase components as well as a
Ubc6 variant lacking the UBC core domain (Ubc6∆UBC). Increased expression levels
of Ubc6 variants, Ubc7 and Cue1 were induced with high copy plasmids. Elevated
Doa10 protein levels were generated by substitution of the Doa10 promoter with the
TEF-promoter. Turnover of Deg1-GFP2 in ∆ubc6 cells served as negative control.
Samples were analyzed by SDS-PAGE and immunoblotting and probed for GFP and
Sec61 (loading control). (b) Quantification of GFP signals from cycloheximide exper-
iments as exemplary shown in (a) (except for Ubc6∆UBCoe). Error bars represent
standard deviation of mean from at least 3 independent experiments.
88
Characterization of the Ubc6 overexpression phenotype
Turnover of another Doa10 substrate Sbh2, which is degraded with a half-
life of less than 10min, appears to be only moderately affected by elevated
Ubc6 levels (figure 3.32 a,b). Because proteolysis of Sbh2 is only partially
dependent on Ubc6, questions were raised if UBC6 overexpression only affects
Doa10 substrates, which absolutely require this E2 for degradation. However,
proteolysis of Sbh2∆4K, a Sbh2 variant whose turnover fully dependents on
Ubc6 (figure 3.26), was impaired to an extent as the wt protein when Ubc6
was overproduced (data not shown). Therefore, special characteristics of this
substrate must account for the robustness of its degradation under Ubc6
overproduction conditions.
Figure 3.32 – Sbh2 turnover is only marginally affected by elevated Ubc6
levels. (a) Cycloheximide decay assay monitoring Sbh2 turnover in cells devoid
of SSH1. Overexpression of UBC6, UBC7 and CUE1 was induced with high copy
plasmids. Samples were analyzed by SDS-PAGE and immunoblotting and probed
for Sbh2 and Sec61 (loading control). (b) Quantification of Sbh2 signals from
cycloheximide experiment presented in (a).
UBC6 overexpression was shown to have a significant impact on degradation
of a large number of Doa10 target proteins. To exclude that the overproduction
of a membrane anchored protein affects general ER homeostasis, the turnover
of CPY* was monitored (figure 3.33). CPY* is an instable variant of the
vacuolar carboxypeptidase yscY with a glycine to arginine substitution at
position 255 [191]. The mutant protein is unable to fold correctly within
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the ER compartment and is consequently degraded by the Hrd1 but not by
the Doa10 ligase. CPY* proteolysis was slightly impaired when Ubc6 was
overproduced but not as strongly as in ∆ubc7 cells (figure 3.33). This is in line
with the results from the sec61-2 growth assay, in which UBC6 overexpression
allowed the growth of cells to a similar extent as UBC6 or DOA10 knockout
strains (figure 3.29). Furthermore, the stability of Doa10 was assed during
UBC6 overexpression (figure 3.33, Doa10 blot). Ubc6 overproduction did not
cause changes in the amount of Doa10 within cells. Thus diminished Doa10
levels cannot account for the observed degradation defect. Summing up, it can
be assumed that elevated Ubc6 levels have an exclusive impact on the turnover
of Doa10 substrates.
Figure 3.33 – CPY* turnover is not significantly influenced by UBC6 over-
expression. (a) Cycloheximide decay assay monitoring CPY* turnover. Overexpres-
sion of UBC6, UBC7 and CUE1 was induced with high copy plasmids. Degradation
of CPY* in ∆ubc7 cells served as negative control. Samples were analyzed by
SDS-PAGE and immunoblotting and probed for CPY, Doa10 and Sec61 (loading
control).
3.3.2 Ubc6 and Ubc7 do not compete for binding to Doa10
In section 3.3.1 it was demonstrated that elevated UBC6 expression impairs
proteolysis of Doa10 client proteins. This observation indicates that Ubc6
and Ubc7 might compete for recruitment to the Doa10 ligase. To verify this
assumption, native immunoprecipitation experiments were performed to study
the level of both E2 enzymes under different overexpression conditions (figure
3.34). Strikingly, Ubc6 levels were extremely low under wt conditions at the
Doa10 ligase but strongly elevated when overproduced (compare lane 1 with
lane 4 in figure 3.34). However, overproduction of Ubc6 did not diminish
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the amount of Ubc7 and Cue1, which co-precipitated with the Doa10 ligase
(compare lane 1 with lane 4 in figure 3.34). Of note, residual amounts of Ubc6
bound unspecifically to the sepharose but co-precipitated amounts were still
significantly increased in presence of the ligase (compare lane 2 with lane 3 or
4 in figure 3.34).
Figure 3.34 – Overproduction of Ubc6 does not deplete Ubc7 from the
Doa10 ligase. Immunoprecipitation experiments of C-terminal Myc-tagged Doa10
were performed under native conditions. Ubc6 or/and Ubc7/Cue1 as well as a
truncated Ubc6 variant lacking its catalytically UBC domain (Ubc6∆UBC) were
overproduced with high copy plasmids. Negative controls in lane 2 and 7 did not con-
tain Myc-tagged Doa10. Samples were analyzed by SDS-PAGE and immunoblotting
and were probed for Doa10, Ubc6, Cue1 and Ubc7. The here presented experiment
was performed by Jasmin Schlotthauer.
An overexpressed truncated Ubc6 variant (Ubc6∆UBC), which consists of
the linker and trans-membrane region but omits the catalytic UBC domain,
was stably recruited to the Doa10 ligase (figure 3.34 lane 6). Interestingly, the
amount of endogenous Ubc6, which bound to the Doa10 ligase, did not change
upon this increased presence of a Ubc6 fragment at the ligase complex. This
observation indicates, that Ubc6 binding to the Doa10 ligase is not saturated
under wt conditions, which in turn allows the increased recruitment of this E2
enzyme to the ligase when overproduced within cells. Summing up, it becomes
evident, that Ubc6 levels seem to be tightly controlled at the Doa10 ligase. In
turn, manipulating UBC6 expression disturbs this fine balance and results in
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elevated levels of the E2 enzyme at the ligase complex.
Figure 3.35 – Overexpression of Ubc6 does not influence substrate re-
cruitment to the Doa10 ligase. Immunoprecipitation experiments of C-terminal
Myc-tagged wt Doa10 and an inactive RING mutant Doa10C93S were performed
under native conditions. Ubc6 or/and Ubc7/Cue1 were overexpressed with high copy
plasmids and the model substrate Deg1-GFP2 was expressed from an ARS/CEN
plasmid. The negative control in lane 1 did not contain Myc-tagged Doa10. Samples
were analyzed by SDS-PAGE and immunoblotting and were probed for Doa10, GFP,
Ubc6, Cue1 and Ubc7.
Ubc6 is a substrate of the Doa10 ligase and its overexpression could influence
the recruitment of other client proteins to the complex. To investigate this
possibility, Doa10 was precipitated under overexpression conditions of UBC6 or
UBC7/CUE1 in presence of the model substrate Deg1-GFP2. Co-precipitated
amounts of the substrate under different overexpression conditions were studied.
Because Deg1-GFP2 is a short-lived protein and cannot be easily detected at
the ligase under wt conditions (figure 3.35, lane 2), a Doa10 RING mutant was
employed to stall the substrate at the complex (figure 3.35, lane 3, 4 and 5).
This RING mutation did not interfere with the recruitment of the E2 enzymes
to the ligase complex. Thus, it can be assumed that both proteins form stable
interactions with the Doa10 protein besides the RING domain. This assumption
is supported by the observation that a Ubc6 fragment just containing the linker
and trans-membrane region of Ubc6 (Ubc6∆UBC) accumulates at the ligase
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(figure 3.34, lane 6). Overexpression of either one of the E2 enzymes did not
influence the amount of Deg1-GFP2, which co-precipitated with the ligase. Thus
it can be assumed, that Ubc6 levels do not influence the binding of cytosolic
clients to the Doa10 ligase. However, influences of UBC6 overexpression on
recruitment of integral-membrane clients to Doa10 should be also evaluated in
future.
3.3.3 Doa10 substrates are ubiquitylated when UBC6 is
overexpressed
It was demonstrated that overproduction of Ubc6 influences the ligase com-
position by elevating levels of the E2 enzyme at the Doa10 complex. Hence,
the ubiquitylation status of substrates should be studied to understand the
consequences of increased amounts of Ubc6 at the ligase. Immunoprecipitation
of overexpressed Ubc6 clearly indicates, that Ubc6 is mono-ubiquitylated under
these conditions (figure 3.36, Ubc6 and Ub blot). Since such a modification was
observed even in absence of the Doa10 ligase (figure 3.17), it does not serve as an
indicator for the ubiquitylation capacity of the ligase. Poly-ubiquitylated Ubc6
species could not be reliably identified from the Ub blots (see also figure 3.17).
It appears, that higher molecular weight Ub signals are present under UBC6
overexpression conditions. If these signals are generated by poly-Ub species or
multiple mono-Ub moieties attached to Ubc6 remains elusive. Summing up,
Ubc6 is not a suitable Doa10 substrate to study changes in the ubiquitylation
pattern upon UBC6 overexpression at the ligase.
Vma12-DegAB is a Doa10 model substrate, which is an excellent tool to
study the ubiquitylation capacity of the Doa10 ligase [155, 192]. Initial immuno-
precipitation experiments indicate that Vma12-DegAB is still ubiquitylated
when Ubc6 is overproduced to a similar extent in wt, but the Ub chain composi-
tion is not studied so far (Tommer Ravid and Itamar Cohen unpublished data).
This indicates that Ubc6 overexpression somehow disturbs the proteolytic
signal on Doa10 target proteins, which prevents their subsequent processing
by the proteasome. Further experiments addressing this problem are manda-
tory to understand the mechanistic fundamentals of the UBC6 overexpression
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phenotype.
Figure 3.36 – Overproduced Ubc6 is mono-ubiquitylated. Immunoprecipita-
tion experiments of Ubc6 under wt and overexpression conditions. Samples were
analyzed by SDS-PAGE and immunoblotting and were probed for Ubc6 and Ub.
Mono-ubiquitylated Ubc6 is highlighted with an arrowhead. Unspecific cross-reaction
signals of antibodies are marked with an asterisk.
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4 | Discussion
The Doa10 Ub ligase is a key player in ER-associated protein degradation
(ERAD) and nuclear protein quality control. Its substrate spectrum covers
a huge variety of different clients including cytosolic and nuclear but also
integral-membrane proteins. The proteolysis of a majority of these polypeptides
depends on the activity of two E2 enzymes: Ubc6 and Ubc7. To this date, it was
unknown how the ligase facilitates the ubiquitylation of such a heterogeneous
substrate pool and which role Ubc6 and Ubc7 play in this process. In this
study it was demonstrated that Ubc6 and Ubc7 act in a sequential manner
at the Doa10 ligase to ensure efficient poly-ubiquitylation of target proteins.
Both enzymes exhibit highly specialized activities during the ubiquitylation
cascade at the Doa10 complex. The ability of Ubc6 to attach Ub moieties not
only to lysine residues within a substrate but also to hydroxylated amino acids
like serine and threonine residues expands the target range of Doa10 towards
clients that do not expose suitable lysine residues as Ub acceptor sites.
4.1 Ubc6 and Ubc7 act in a sequential manner
on Doa10 substrates
Genetic data imply that proteolysis of Doa10 client proteins depends on the
enzymatic activity of the Ub conjugating enzymes Ubc6 and Ubc7 (figure 3.1)
[136, 141, 170]. In this study, it was demonstrated that both enzymes act in a
successive manner on Doa10 substrates to facilitate efficient poly-ubiquitylation.
In a first reaction step, Ubc6 conjugates single Ub moieties to Doa10 substrates.
This is followed by an extension of these moieties with K48-linked poly-Ub
chains, which are synthesized by Ubc7 (figure 4.1). These conclusions are
mainly based on in vitro observations. Recent work analyzed the contribution
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of Ubc6 and Ubc7 in the processing of Doa10 substrates in vivo [155]. The
authors observed that the Doa10 substrate Vma12-DegAB is decorated with
low molecular weight Ub moieties in absence of Ubc7. In cells devoid of Ubc6 or
Doa10 no modification of the Doa10 client was detected. Under wt conditions,
Vma12-DegAB was heavily poly-ubiquitylated with K48-linked Ub chains. Fur-
thermore, Weber et al. were able to bypass the necessity for Ubc6-mediated Ub
chain initiation by fusing Ub molecules to Doa10 target proteins. In summery,
these in vivo data support the conclusions from this study and the postulated
model for Doa10 substrate ubiquitylation. Similar consecutive ubiquitylation
models were recently proposed for the APC and SCFβTrCP2 ligase complexes
as well as for auto-ubiquitylation of the RING ligase BRCA1 [95, 183, 193].
Nevertheless, this study verifies for the first time the requirement for such a
tandem ubiquitylation mechanism during protein quality control (PQC). PQC
client proteins are highly diverse in their structural properties and amino acid
composition [194]. Hence, the initial attachment of a Ub molecule to an accep-
tor site within differing peptide environments provides a challenge for PQC
ligases [195]. Consequently, a tandem ubiquitylation model, as presented in
figure 4.1, may account for an adaptation of the Doa10 ubiquitylation capacity
towards a diverse protein landscape of its clients.
To this date, tandem ubiquitylation models have been proposed for a small
number of Ub ligases and only for Doa10-mediated quality control a biological
relevance was shown in vivo [95, 155, 183, 193]. However, recent work suggests
that such sequential engagement of E2 enzymes is a more common phenomenon,
especially in higher eukaryotes. The E2 enzyme Ube2W, for example, attaches
single Ub moieties to the disordered N-terminus of its client proteins in human
[196, 197]. It was proposed that Ube2W together with Ube2N sequentially
ubiquitylate the cytosolic antibody receptor TRIM21, which in turn activates
the removal of antibody-coated virus particles during innate immunity [198].
Appointed combinations of E2 enzymes seem to be of advantage to allow
flexible adaptation to certain cellular requirements and provide an additional
layer of regulation to the ubiquitylation of proteins. Concordantly, much more
effort must be put into identifying relevant E2-E3 ligase complexes in vivo
and investigation of tandem ubiquitylation models on a broad range. It seems
96
Ubc6 and Ubc7 act in a sequential manner on Doa10 substrates
feasible to regard the inventory of E2 enzymes within the cell as a toolbox
containing a number of instruments with differing abilities to catalyze Ub
linkages. The preferences of certain E2 enzymes for some ligases as well as
their restriction to certain cellular compartments ensures the tight regulation
and specificity of the Ub code.
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Figure 4.1 – Schematic representation of the enzymatic activities of Ubc6
and Ubc7 towards Doa10 clients. Ubc6 adds single Ub species to lysine residues
(K) but also to hydroxylated amino acids as serine (S) and threonine (T) within Doa10
target proteins. This priming step allows the subsequent attachment of K48-linked
poly-Ub chains by Ubc7. In some instances, Ubc7 is able to initiate ubiquitylation
directly on Doa10 substrates. However, this event appears to be less efficient as
compared to the priming reaction catalyzed by Ubc6. The figure was adapted from
Weber et al. [155].
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4.2 Ubc6 predominantly attaches single Ub moi-
eties to Doa10 client proteins
Ubc6 and Ubc7 fulfill distinct functions in the ubiquitylation of Doa10 client
proteins. Ubc6 initiates ubiquitylation by attaching single or presumably low
molecular weight Ub species to a target protein. In this process, Ubc6 is highly
flexible in choosing ubiquitylation sites (section 3.1.4). Concordantly, it was
shown that Ubc6 is not able to form significant amounts of poly-Ub chains in
vitro (section 3.1.5). Furthermore, the low molecular conjugates synthesized
by Ubc6 do not exhibit a homogenous Ub-linkage type but contain a mixture
of K48- and K63-linked Ub species. This matches the observation that the
activity of Ubc6 alone cannot promote the proteolysis of Doa10 target proteins.
Thus, Ubc6 is not able to generate a Ub signal, which is recognized by the 26S
proteasome. In a recent publication, Xu et al. reported that Ubc6 primarily
catalyzes K11-linked and, with lesser efficiency, also other Ub chains in vitro
[28]. The authors used prolonged incubation times of about two hours for their
assays. In the present work the typical reaction times were much shorter and
no evidence for Ub chain synthesis by Ubc6 was found. This is further proof for
the limited ability of Ubc6 to synthesize higher Ub conjugates. Concordantly,
the biological relevance of a chain forming activity by Ubc6 remains to be
determined in vivo in presence of the highly processive Ub chain elongating
enzyme Ubc7. A question, which is yet not answered, concerns the preference
of Ubc6 to catalyze mono-ubiquitylation. Studies characterizing structural
features in E2 enzymes, which prevent Ub chain formation, are limited to
date. Recent work indicates that a disordered N-terminal extension limits
poly-Ub chain formation of the UBE2E Ub conjugating enzyme family [103].
A C-terminally truncated Ubc6 variant (Ubc6∆L) did not exhibit changes in
its catalytically activity suggesting that the activity of this E2 is not restricted
by this extension (figure 3.4 b). For other E2 enzymes as UbcH5 and Ube2S, it
was suggested that backside binding of a free Ub molecule increases processivity
in Ub chain formation [100, 199]. Interestingly, a similar mechanism was also
proposed to inhibit chain formation for other E2 enzymes [101]. It remains to
be determined if Ubc6 interacts through such a backside binding site with Ub
and how this influences the overall activity of the E2 enzyme. The surface of
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Ubc6 exhibits a positive electrostatic potential, which is rather unusual for an
E2 enzyme [200]. This characteristic might account for the unique catalytic
propensities of Ubc6 and its family members. Another factor, which seems
to determine the activity of E2 enzymes, is the binding strength of the E2
enzyme to the E3 RING domain [101]. Strong E2-E3 interactions reduce the
conformational freedom of the E2-bound Ub moiety, which in turn promotes
Ub chain formation. Generally, further structural and mutational studies are
required to shed light on the reasons that restrict the ubiquitylation capacity
of Ubc6 towards Ub chain elongation.
4.3 Ubc7 is a highly specialized E2 enzyme syn-
thesizing K48-linked Ub chains
In contrast to Ubc6, Ubc7 efficiently catalyze K48-linked poly-Ub chains (sec-
tion 3.1.5 and [142]). An acidic loop close to the catalytic center of Ubc7 (figure
4.2) presumably positions lysine 48 of the acceptor Ub molecule in favor for an
attack by the donor Ub [94, 143, 201]. These structural characteristics probably
limit the ability of Ub7 to attach Ub moieties directly to client proteins. Lysine
residues in target proteins might be difficult to access and located in various pep-
tide environments, which in turn complicates mounting of the first Ub by Ubc7.
This assumption is validated by the observation that the Doa10 substrates Sbh2
(figure 3.26) and also a mutant variant of the ATP-binding cassette a-factor
transporter Ste6* can be still degraded in absence of Ubc6 although in a less
efficient manner [170, 187, 202]. A similar behavior was also shown for other
chain specific E2 enzymes UBE2S (K11 specific) and UBE2N-UBE2V1 (K63
specific), which lack the capability for Ub chain initiation [96, 183, 203, 204]. In
contrast, Cdc34 is able to catalyze both the initiation and the elongation with
K48-linked Ub chains [94]. However, the attachment of the first Ub molecule
is extremely slow and rate limiting when compared to the subsequent rapid
synthesis of poly-Ub chains. Consequently, the Doa10 ligase employs two E2
enzymes to circumvent this limitation. Because Ubc7 is extremely proficient
in generating Ub signals, which are recognized by the 26S proteasome, it is
mandatory to constrain its activity and prevent unspecific protein degradation.
This is partially archived through its interaction partner Cue1, which controls
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recruitment of Ubc7 to the ER-membrane and stimulates its activity [144–146].
Additionally, the necessity for Ubc6 to initiate ubiquitylation might serve as
another layer of regulation to control Ubc7 activity at the Doa10 ligase.
Ubc7 is also part of the protein quality control ligase Hrd1, which facilitates
the ubiquitylation of ER luminal and ER integral-membrane clients [149, 205].
Strikingly, Ubc7 is the only E2 enzyme, which is known to be required for the
decoration of Hrd1 clients with K48-linked Ub chains. Presumably, Ubc7 is
able to initiate ubiquitylation in the context of this ligase. Hrd1 target proteins
are partially unfolded during their retro-translocation to the cytosol, which
might allow access of Ubc7 to appropriate ubiquitylation sites. Additionally,
the Doa10 and Hrd1 RING domains differentially stimulated chain elongation
catalyzed by Ubc7 [158]. Cohen et al. propose, that the Hrd1 RING domain
stabilizes the closed conformation of the Ubc7˜Ub conjugate substantially
better than the Doa10 RING domain, which might in turn affect processivity of
Ubc7 [82, 83, 111]. Nevertheless, circumstances, which enable Ubc7 to directly
ubiquitylated client proteins, need to be studied in more detail.
4.4 The unique properties of the Ub conjugation
enzyme Ubc6 are conserved in human
UBE2J2, the human Ubc6 orthologue, displays comparably ubiquitylation
activity in vitro as the yeast protein (figure 3.6). Furthermore, both proteins
share a high degree of sequence identity in the catalytically core domain, which
most likely determines their enzymatic activity [172, 173]. Thus, it seems
feasibly that UBE2J2 also acts as priming E2 enzyme in human protein quality
control. This is supported by the observation that the human orthologue of
Ubc7, UBE2G2, co-localizes with UBE2J2 and both proteins are implicated in
ER associated protein degradation (ERAD) [206, 207]. Immunoprecipitation
experiments indicated that UBE2J2 interacts with the ligase TMEM129 in
the ubiquitylation of MHC class I molecules during virus infection [208, 209].
However, it is not the only E2 enzymes whose depletion diminished proteolysis
of TMEM129 target proteins. UBE2K, which specifically catalyzes the synthesis
of K48-linked Ub chains, is also required for the degradation of MHC class I
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proteins [98, 208, 210]. Thus, both enzymes presumably act sequentially on
TMEM129 client proteins but further proof for such a tandem ubiquitylation
mechanism is still missing. ERAD in higher eukaryotes is more complex when
compared to yeast. Consequently, only a few functional E2-E3 pairs of this
process are characterized to date. Further studies are required, to validate
a priming function of UBE2J2 in vivo and identify the involved Ub ligase
complexes.
Similar to Ubc6, UBE2J2 is a short-lived protein, whose turnover depends
on its own catalytically activity [211]. The linker region of Ubc6 was shown to
convey degradation [152]. The corresponding area of Ubc6 is predicted to be
unstructured (IUPred [212], data not shown). Most disordered regions are not
conserved during evolution because they do not depend on a defined structural
fold to fulfill their function [213]. Concordantly, the linker regions of human
UBE2J2 and yeast Ubc6 differ in their sequence (figure 3.6). However, the
overall length of this segment is similar. Auto-ubiquitylation of UBE2J2 was
not detected in the course of the in vitro ubiquitylation assay (figure 3.6). Thus,
further experiments are necessary to determine, if the human E2 enzymes is also
ubiquitylated within its linker region and to identify the ligase that controls the
proteolysis of the protein. It can be speculated that the constitutive turnover
of Ubc6 family members might represent a regulatory aspect to control the
enzymatic activity of this protein family.
4.5 Ubiquitylation of hydroxylated amino acids
expands the Doa10 target range
Previous studies indicate that hydroxylated amino acids serve as Ub acceptor
sites in protein degradation [70, 73, 75]. Asi2, a Doa10 substrate, was degraded
even when all internal lysine residues were substituted to arginine residues
[214]. Additionally, Boban et al. were able to show that the ubiquitylation of
this lysine less Asi2 variant was susceptible to high pH levels, implying that the
ubiquitylation of this mutant occurs on hydroxylated amino acids. In this study,
the ability of Ubc6 to catalyze the attachment of Ub to serine or threonine
residues was directly shown by mass spectrometry (figure 3.22). It was demon-
101
Discussion
strated that ubiquitylation of hydroxylated amino acids plays an important role
during auto-ubiquitylation of Ubc6 and Doa10 client ubiquitylation in absence
of accessible lysine residues (section 3.2.2 and 3.2.4). There were no hints that
Ubc6 is able to attach Ub moieties to cysteine residues or to the N-terminus
of a protein, though this particular issue was not systematically investigate
in the course of this study. Furthermore, it needs to be determined if Ubc6
preferentially attaches Ub to lysine residues rather than to hydroxylated amino
acids or if the general accessibility of the available amino acids in a target
protein plays a more important role during Ub chain initiation.
Previous studies postulated that E3 ligases modulate the activities of E2
enzymes to conduct the ubiquitylation of serine or threonine residues. In con-
trast, this study demonstrates that the catalysis of such ubiquitylation events
depends primarily on the intrinsic propensities of Ubc6. Initial studies showed
that the ubiquitylation of some natural ERAD substrates in human is pH labile
[75]. Moreover, proteolysis of the T-cell Antigen Receptor α-Chain is facilitated
by ubiquitylation of non-lysine residues [74, 215]. Still, it is not clear at the
moment, how abundant ubiquitylation of hydroxylated amino acids is within
cells. However, it can be assumed that it is more widespread than anticipated
since most high throughput screens to identify ubiquitylated proteins and ubiq-
uitylation sites employ protocols that disassemble oxyester and also thioester
linkages. Thus, high throughput screens with milder conditions preserving
these linkage types need to be conducted to survey the actual distribution of
such non-canonical ubiquitylation events.
The active site region of Ubc6 exhibits significant differences from reactive
centers of other E2 enzymes in yeast (red box in figure 4.2). Especially, the HPN
motive close to the active site cysteine residue is implicated in being mandatory
for structural arrangements within the catalytic center [80, 81]. Because these
and other residues are not conserved in Ubc6, the enzyme most likely employs
a different catalytic strategy for Ub transfer. The unique properties of the
Ubc6 active site region, which are preserved in eukaryotes, might account for
the flexibility of this class of E2 enzymes in choosing ubiquitylation sites (figure
3.6 and [172]). This assumption is supported by observations reporting that
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UBE2J2 might ubiquitylate MHC class I proteins on hydroxylated amino acids
during viral infection [216]. The conservation of these unique propensities of the
Ubc6 E2 enzyme family most likely reflects the requirement for such an activity
in PQC systems to ensure degradation of target proteins exposing unusual
features with inaccessible or no lysine residues. Malfolded proteins most likely
do not expose a homogenous conformation but collapse randomly. Thus, indi-
vidual proteins might expose different sequence properties and ubiquitylation
must be initiated at different sites. Consequently, the ability of Ubc6 to target
not only lysine residues but also hydroxylated amino acids most likely ensures
the efficient degradation of all conformers of a malfolded client protein.
Interestingly, the number of non-canonical ubiquitylation events in ERAD
seems to increase during viral infections. The HIV virus for example initiates
the ubiquitylation of BST-2, an immunity regulator, on cysteine, serine and
threonine residues for degradation to weaken the immune response of the
host [68]. Degradation of MHC class I proteins after infection by human
cytomegalovirus and herpesvirus was shown to depend on UBE2J2 [73, 208, 216].
It is not known, whether viruses preferentially engage UBE2J2 for degradation
of host proteins. However, the utilization of a promiscuous E2 enzyme to trigger
degradation of normally stable host proteins appears to be of advantage for
virus propagation.
4.6 Implications of Ubc6 turnover on Doa10 lig-
ase function
Ubc6 is a short-lived protein with a half-life of about 55min [133, 152]. Its
proteolysis depends on its catalytic activity and on Ubc7 and Doa10 (figure
3.14). In the course of this study no indications for a regulatory functions
of Ubc6 turnover were obtained. Unfortunately, Ubc6 variants that were
catalytically active but were not subjected to constant degradation are not
available. Previous observations of Kreft et al. indicate that Ubc6 proteolysis
is not a prerequisite for the function of the Doa10 ligase in vivo [217]. They
mutated a highly conserved glutamate residue within the 5th trans-membrane
domain of the Doa10 ligase, which results in diminished or accelerated Ubc6
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Figure 4.2 –Multiple sequence alignment of yeast Ub conjugating enzymes.
Clustal Omega sequence alignment [175] of the catalytic core domains of nine E2
enzymes from yeast. The alignment was edited with Jalview and colored according to
BLOSUM62 (BLOcks SUbstitution Matrix) [176]. The conserved active site cysteine
is marked with an asterisk and the surrounding amino acids are highlighted with a
red box.
turnover dependent on the amino acid substitution. Processing of other Doa10
client proteins was not affected by these mutations. Kreft et al. propose
that Ubc6 can occupy at least two different binding sites at the ligase: one is
responsible for Ub transfer from Ubc6 to a substrate whereas the other might
be a general site for binding of integral-membrane clients. However, the authors
could not provide a mechanistic explanation for their observations and further
studies are required to understand their findings. Ubc6 auto-ubiquitylates
itself in absence of the Doa10 ligase in vitro and in vivo (section 3.1.7). This
phenomenon has been observed for several other E2 enzymes before [174].
The E2 enzyme Ube2T was shown to mono-ubiquitylate itself at a certain
lysine residue within its catalytically core domain, which in turn restricts its
ubiquitylation capacity towards client proteins [218]. To investigate, if a similar
auto-regulatory mechanism also applies for Ubc6 function, ubiquitylated Ubc6
was purified. Due to residual amounts of unmodified Ubc6, which unspecifically
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bound to the affinity resin, a definite conclusion could not be drawn from these
experiments (section 3.1.7). However, it was observed that Ubc6 is able to
attach several mono-Ub species to itself in cis during the in vitro ubiquitylation
assay (figure 3.15). Hence, it seems improbable that the activity of Ubc6 is
restricted when a Ub moiety is fused to its C-terminal region because the
enzyme can attach an additional Ub molecule to a different acceptor site
within its linker region. Another indication for this assumption is the lack of
a specific ubiquitylation site within Ubc6 (section 3.2.1). Because Ubc6 was
stronger mono-ubiquitylated in cell devoid of DOA10 than in cells lacking Ubc7,
questions were raised whether Ubc6 ubiquitylation can only take place when the
E2 is not bound to the Doa10 ligase. The disordered linker region of Ubc6 might
be quite flexible in absence of a binding partner, which presumably allows free
access to this area for Ub transfer. In context of the Doa10 ligase the dynamics
of this region could be much more constrained and certain amino acids might
not be accessible for Ub conjugation. Based on this assumption unmodified
Ubc6 would stay at the ligase and mainly attach Ub moieties to Doa10 target
proteins. Ubc6, which is not engaged by Doa10, would ubiquitylate itself
and possibly be recruited to the aforementioned integral-membrane substrate
binding site of the Doa10 ligase for poly-ubiquitylation by Ubc7. The proposed
model seems conceivably, through there are many open questions, which need
to be addressed in order to validate such a scenario.
4.7 Regulation of Ubc6 and Ubc7 activity at the
Doa10 ligase
Tandem ubiquitylation mechanisms may represent a more general phenomenon
in the Ub field to allow efficient poly-ubiquitylation of target proteins. However,
it is little known how ligase complexes orchestrate the activity of two sequentially
acting E2 enzymes. The anaphase promoting complex (APC) was the first
ligase, which was shown to employ two E2 enzymes in substrate ubiquitylation
[95]. For human APC, it was demonstrated that priming and elongating E2
enzymes depend on different binding sites at the complex to enable their optimal
performance during ubiquitylation [181]. The Ub chain elongating enzyme is
positioned favorably towards the acceptor Ub molecule in order to increase
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processivity, which in turn counteracts the activity of the chain initiating E2
enzyme. The yeast APC complex employs the E2 enzyme Ubc4 (initiating
E2) and Ubc1 (elongating E2) for substrate ubiquitylation. Both enzymes are
thought to compete for the same binding site at the ligase. A recent study from
Girard et al. proposes that the UBA domain of Ubc1 increases the affinity for
the APC complex, which in turn enhances its ability to compete with Ubc4 for
binding [219]. In the presented study it was shown that Ubc6 and Ubc7 occupy
the same docking site on the Doa10 RING domain (section 3.1.6). However, no
evidence was found that high amounts of Ubc6 or Ubc7/Cue1 diminish Doa10R
poly-ubiquitylation in vitro (data not shown). Interactions of E2 enzymes with
RING domains are very transient and dynamic [13, 92]. If Ubc6 and Ubc7
display different affinities for the RING domain remains elusive and further
studies are necessary to determine dissociation constants for the individual
E2 enzymes with Doa10R. Additional interaction surfaces of the ligase could
increase the affinity for certain E2 enzymes as for example shown for Ubc1 and
the APC complex [219]. The trans-membrane anchor of Ubc6 was shown to be
important for interaction with the Doa10 ligase [151, 152, 217]. If the linker
region of Ubc6 specifically interacts with parts of the E3 ligase is not know
to date. Ubc7 is recruited by its adapter protein Cue1 to the ER membrane
[144]. Co-localization of the Ubc7/Cue1 complex to Doa10 depends on the
N-terminal trans-membrane anchor of Cue1 (unpublished data). Furthermore,
a C-terminally truncated Doa10 variant abolishes Ubc7 recruitment [217].
Hence, both E2 enzymes Ubc6 and Ubc7 are stably recruited to the Doa10
ligase most likely through interactions of trans-membrane segments. This was
further validated by observations that Ubc6 and Ubc7 co-localize with Doa10
even when the RING domain is disrupted (figure 3.35). Additionally, both
E2 enzymes bind in the absence of the other enzyme to the ligase complex
[201]. Thus, it can be excluded that Ubc6 recruitment must occur prior to the
recruitment of Ubc7 to Doa10. How both E2 enzymes interact with Doa10
in detail remains elusive. Nevertheless, it can be speculated that there is a
mechanism, which increases the processivity of Ubc7 towards K48-linked Ub
chain synthesis upon initiation of the ubiquitylation cascade. Such a stimulation
of Ubc7 activity might outperform the relatively low Ub-conjugating activity
of Ubc6. Studies on Cue1, for example, demonstrated that the processivity
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of Ubc7 chain elongation correlates with the increasing length of the acceptor
Ub chain whereas the stimulatory influence of the RING domain decreases
(unpublished data, Maximilian von Delbrück, AG Sommer). In such a scenario,
Ubc7-mediated chain elongation would be a self-stimulatory process when Ubc6
initiated the ubiquitylation in a prior step.
4.8 Overproduction of Ubc6 interferes with the
integrity of the Doa10 ligase
UBC6 was initially identified as E2 encoding gene that when overexpressed sup-
presses the temperature sensitive growth defect of a sec61-2 yeast strain [151].
Further studies revealed that the deletion as well as the increased expression of
this gene abolishes the degradation of the folding-deficient Sec61-2 protein and
other ERAD substrates [151, 173, 220]. Obviously, a defined amount of Ubc6 is
required for the degradation of Doa10 substrates, whereas an excessive portion
impairs this process (section 3.3.1). One explanation for this phenomenon is
competition of the E2 enzymes Ubc6 and Ubc7 for binding to the ligase. How-
ever, this assumption was excluded because Cue1 and Ubc7 levels were not alter
at the ligase upon the overproduction of Ubc6. Additionally, increased levels
of Ubc7/Cue1 did not supress the UBC6 overexpression phenotype. Elevated
cellular amounts of Ubc6 lead to a tremendous increase of the Ubc6 population,
which co-localized with Doa10 when compared to the wt situation. Thus, Ubc6
level seem to be not saturated under wt conditions. The negative effect of
UBC6 overexpression was subjected to its catalytically core domain since the
overproduction of a truncated Ubc6 variant, lacking the UBC domain, did
not interfere with Doa10 dependent substrate proteolysis. Initial experiments
indicate that Doa10 substrates are still ubiquitylated upon overproduction
of Ubc6. Hence, increased levels of Ubc6 at the Doa10 ligase might disrupt
the Ub signal initiating degradation, which is normally generated when E2
levels are balanced. Two scenarios can be envisioned: On the one hand, Ubc6
could attach Ub moieties to random lysine residues within the growing Ub
chain and thereby disrupt the homogeneity of the chain. In consequence, the
client protein would not be further processed by downstream factors such as
the proteasome. On the other hand, Ubc6 could attach multiple mono-Ub
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moieties to the substrate, which in turn may perturb Ubc7 processivity due
to the increased number of presented Ub acceptor sites. De-ubiquitylating
processes always counteract ubiquitylation reactions. The ER localized deu-
biquitylating enzyme Ubp1 might interfere with Doa10-mediated proteolysis
[221]. An increased retention time of substrates during ubiquitylation most
likely raises the possibility for Ubp1 or other DUBs to remove already attached
Ub moieties thereby preventing their efficient degradation [222]. Additionally,
multiple mono-Ub could also impede the optimal orientation of Ubc7 for Ub
donor transfer towards the Ub acceptor molecule due to steric restrictions of
neighboring Ub molecules [94, 223]. A similar scenario was observed at the
SCFβTrCP2 ligase complex [193]. High amounts of UbcH5, the Ub chain initiat-
ing E2 enzyme, resulted in hyper-mono-ubiquitylation of the substrate, which
interfered with subsequent chain elongation. However, mechanistic reasons for
this observation remain elusive. Ubc6 is known to mono-ubiquitylate itself at
several residues in one molecule. Thus, it seems likely that Ubc6 is able to
attach several Ub moieties also to one substrate molecule in vivo. This would
also explain, why degradation of the small Doa10 substrate Sbh2 is not affected
by elevated Ubc6 levels (figure 3.32). Due to its limited size Ubc6 might not be
able to attach multiple Ub moieties to Sbh2. Hence, the substrate is processed
almost with similar half-life during UBC6 overexpression as compared to wt
conditions. Nevertheless, extensive investigations are necessary to understand
the mechanistic reasons for the UBC6 overexpression phenotype.
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